

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 586 333 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
19.10.2005 Bulletin 2005/42

(51) Int Cl.7: **A61K 45/06, A61P 35/00**

(21) Application number: **05090011.7**

(22) Date of filing: **20.06.2001**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**
Designated Extension States:
LT LV RO SI

(30) Priority: **23.06.2000 EP 00250194**
28.06.2000 EP 00250214

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
01965012.6 / 1 292 335

(71) Applicant: **Schering Aktiengesellschaft**
13353 Berlin (DE)

(72) Inventors:
• **Siemeister, Gerhard**
13503 Berlin (DE)
• **Haberey, Martin**
12169 Berlin (DE)
• **Thierauch, Karl-Heinz**
14159 Berlin (DE)

Remarks:

This application was filed on 27 - 01 - 2005 as a
divisional application to the application mentioned
under INID code 62.

(54) **Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie
receptor function and their use (II)**

(57) The present invention describes the combina-
tion of substances interfering with the biological activity
of Vascular Endothelial Growth Factor (VEGF)/VEGF

receptor systems (compound I) and substances inter-
fering with the biological function of Angiopoietin/Tie re-
ceptor systems (compound II) for inhibition of vascular-
ization and for cancer treatment.




Fig. 1

Description

[0001] The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

[0002] Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family. The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PlGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonpierre et al., Science 277, 55-60, 1997; Valenzuela et al., Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).

[0003] The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442, 1996). Mice carrying homozygous disruptions in either Flt1 or Flk1/KDR gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that Flk1/KDR knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al., Nature 376, 62-66, 1995), whereas Flt1 deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the Flt4 gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of Flt4 for the remodeling and maturation of the primary vascular networks into larger blood vessels during early development of the cardiovascular system (Dumont et al., Science 282, 946-949, 1998). Consistent with the lymphatic expression of Flt4 in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch et al., Science 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., Proc. Natl. Acad. Sci. USA 95, 14389-14394, 1998).

[0004] The second class of endothelial cell specific receptor tyrosine kinases has also been found to be critically involved in the formation and integrity of vasculature. Mice deficient in Tie1 die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., Nature 376, 70-74, 1995; Rodewald & Sato, Oncogene 12, 397-404, 1996). The Tie2 knock-out phenotype is characterized by immature vessels lacking branching networks and lacking periendothelial support cells (Sato et al., Nature 376, 70-74, 1995; Dumont et al., Genes Dev. 8, 1897-1909, 1994). Targeted inactivation of the Tie2 ligand Ang1, as well as overexpression of Ang2, an inhibitory ligand, resulted in phenotypes similar to the Tie2 knock out (Maisonpierre et al., Science 277, 55-60, 1997; Suri et al., Cell 87, 1171-1180). Conversely, increased vascularization was observed upon transgenic overexpression of Ang1 (Suri et al., Science 282, 468-471, 1998; Thurston et al., Science 286, 2511-2514, 1999).

[0005] The results from angiogenic growth factor expression studies in corpus luteum development (Maisonpierre et al., Science 277, 55-60, 1997; Goede et al., Lab.

[0006] Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., Nature Med. 1, 1024-1028, 1995; Benjamin et al., Development 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of endothelial-periendothelial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, Science 277, 48-50, 1997).

[0007] In pathological settings associated with aberrant neovascularization elevated expression of angiogenic growth factors and of their receptors has been observed. Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., Cancer Res. 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies (Kim et al., Nature 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., Nature 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Gold-

man et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine kinase (Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., Cancer Res. 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al., Cancer Res. 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., J. Clin. Invest. 103, 159-165, 1999).

[0008] The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kai-painen et al., Cancer Res. 54, 6571-6577, 1994), in breast carcinomas (Salven et al., Br. J. Cancer 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., Cancer Res. 56, 1615-1620, 1996), as well as elevated expression of Flt4 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., Cancer Res. 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., Am. J. Pathol. 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., Science 284, 1994-1998, 1999; Holash et al., Oncogene 18, 5356-5362, 1999).

[0009] Interference with Tie2 receptor function by means of Angiopoietin-neutralizing Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al. Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Comparing the effects of interference with the endothelium-specific receptor tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., Nature 367, 576-579, 1994; Kim et al., Nature 362, 841-844, 1993; Millauer et al., Cancer Res. 56, 1615-1620, 1996; Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998; Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Even by escalation of therapeutic doses a plateau level of therapeutic efficacy was achieved (Kim et al., Nature 362, 841-844, 1993; Wood et al. Cancer Res. 60, 2178-2189, 2000). Similar results were observed upon interference with the Angiopoietin/Tie2 receptor system (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al., Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

[0010] However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenic compounds.

[0011] Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-periendothelial cell interaction of existing mature tumor vessels and thereby sensitizes the endothelium to compounds directed against VEGF/VEGF receptor systems.

[0012] Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological activity of one or several of the

VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems and compound II consists of cytotoxic agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems. Targeting or modulation of the biological activities of VEGF/VEGF receptor systems and of Angiopoietin/Tie receptor systems can be performed by


- (a) compounds which inhibit receptor tyrosine kinase activity,
- (b) compounds which inhibit ligand binding to receptors,
- (c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- (d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- (e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- (f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

[0013] A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), Cancer Res. 59, 99-106; Vajkoczy et al., Proc. Am. Associ. Cancer Res. San Francisco (2000), Abstract ID 3612; Zeneca: ZD4190, ZD6474; Wedge et al. (2000), Cancer Res. 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., Proc. Am. Associ. Cancer Res., San Francisco (2000), Abstract ID 3614; Dimitroff et al. (1999), Invest. New Drugs 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is prevented. Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as Pseudomonas exotoxin A, Diphtheria toxin, or Ricin A. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhuMAbVEGF) and by Presta et al. (1997), Cancer Res. 57, 4593-4599. Ligand-binding receptor domains are described by Kendall & Thomas (1993), Proc. Natl. Acad. Sci., U.S.A.90, 10705-10709; by Goldman et al. (1998) Proc. Natl. Acad. Sci., U.S.A.95, 8795-8800 and by Lin et al. (1997), J. Clin. Invest. 100, 2072-2078. Further, dominant negative receptors have been described by Millauer et al. (1994), Nature 367, 567-579. Receptor blocking antibodies have been described by Imclone (c-p1C11, US 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), Proc. Natl. Acad. Sci., U.S.A.95, 4625-4629). High affinity ligand- or receptor binding oligo nucleotides have been described by NeXstar (NX-244) and Drolet et al. (1996), Nat. Biotech 14, 1021-1025. Further, small molecules and peptides have been described.

[0014] Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, Angiozyme™, see RPI Homepage).

[0015] Examples for delivery-/Targeting-Systems have been described as ligand/antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), Cancer Res. 59, 183-188 and Olson et al. (1997), Int. J. Cancer 73, 865-870), as endothel cell targeting of liposomes (Spragg et al. (1997), Prog. Natl. Acad. Sci. U.S.A.94, 8795-8800, and as endothel cell targeting plus coagulation-induction (Ran et al., (1998), Cancer Res. 58, 4646-4653).

[0016] Small molecules which inhibit the receptor tyrosine kinase activity are for example molecules of general formula I



in which

r

n


R₃ und R₄

has the meaning of 0 to 2,

has the meaning of 0 to 2;

a) each independently from each other have the meaning of lower alkyl,

b) together form a bridge of general partial formula II,




wherein the binding is via the two terminal C- atoms, and

m

has the meaning of 0 to 4; or

c) together form a bridge of partial formula III




wherein one or two of the ring members T₁, T₂, T₃, T₄ has the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T₁ and T₄;

G has the meaning of C₁ - C₆ - alkyl, C₂ - C₆ - alkylene or C₂ - C₆ - alkenylene; or C₂ - C₆ - alkylene or C₃ - C₆ - alkenylene, which are substituted with acyloxy or hydroxy; -CH₂-O-, -CH₂-S-, -CH₂-NH-, -CH₂-O-CH₂-, -CH₂-S-CH₂-, -CH₂-NH-CH₂, oxa (-O-), thia (-S-) or imino (-NH-),
 A, B, D, E and T independently from each other have the meaning of N or CH, with the proviso that not more than three of these Substituents have the meaning of N,
 Q has the meaning of lower alkyl, lower alkyloxy or halogene,
 R₁ and R₂ independently from each other have the meaning of H or lower alkyl,
 X has the meaning of imino, oxa or thia;
 Y has the meaning of hydrogene, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and
 Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if more than one rest Z is present (m≥2), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single or double bonds; or an N-oxide of said compound, wherein one ore more N-atoms carry an oxygene atom, or a salt thereof.

[0017] A preferred salt is the salt of an organic acid, especially a succinate.

[0018] These compounds can preferentially be used as compound I or II in the inventive pharmaceutical composition.

[0019] Compounds which stop a tyrosin phosphorylation, or the persistent angiogenese, respectively, which results in a prevention of tumor growth and tumor spread, are for example anthranil acid derivatives of general formula IV




in which


A has the meaning of group =NR²,

W has the meaning of oxygen, sulfur, two hydrogen atoms or the group =NR⁸,

Z has the meaning of the group =NR¹⁰ or =N-, -N(R¹⁰)-(CH₂)_q-, branched or unbranched C₁₋₆-Alkyl or is the group



or A, Z and R¹ together form the group



m, n and o

q

R_a, R_b, R_c, R_d, R_e, R_f

X

Y

p

R¹

R²

R³

R⁴, R⁵, R⁶ and R⁷

has the meaning of 0 - 3,

has the meaning of 1 - 6,

independently from each other have the meaning of hydrogen, C₁₋₄ alkyl or the group =NR¹⁰, and/or R_a and/ or R_b together with R_c and or R_d or R_c together with R_e and/ or R_f form a bound, or up to two of the groups R_a-R_f form a bridge with each up to 3 C-atoms with R¹ or R²,

has the meaning of group =NR⁹ or =N-,

has the meaning of group -(CH₂)_p,


has the meaning of integer 1-4,

has the meaning of unsubstituted or optionally substituted with one or more of halogene, C₁₋₆-alkyl, or C₁₋₆-alkyl or C₁₋₆-alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,

has the meaning of hydrogen or C₁₋₆-alkyl, or form a bridge with up to 3 ring atoms with R_a-R_f together with Z or R₁,

has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of für halogen, C₁₋₆-alkyl, C₁₋₆-alkoxy or hydroxy,

independently from each other have the meaning of hydrogen, halogen or C₁₋₆-alkoxy, C₁₋₆-alkyl or C₁₋₆-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogen, or R⁵ and R⁶ together form the group




R⁸, R⁹ and R¹⁰

independently from each other have the meaning of hydrogen or C₁₋₆-alkyl, as well as their isomers and salts.

[0020] These compounds can also preferentially be used as compound I or II in the inventive pharmaceutical composition.



[0021] More preferentially compounds of geneeral formula V




V,

in which


R¹ has the meaning of group



in which R⁵ is chloro, bromo or the group -OCH₃,



in which R⁷ is -CH₃ or chloro,




in which R^8 is -CH₃, fluoro, chloro or -CF₃

in which R^4 is fluoro, chloro, bromo, -CF₃, -N=C, -CH₃, -OCF₃ or -CH₂OH

in which R^6 is -CH₃ or chloro

R^2 has the meaning of pyridyl or the group



and

R^3 has the meaning of hydrogen or fluoro, as well as their isomers and salts can be used as compound I or II in the inventive pharmaceutical composition.

[0022] These compounds have the same properties as already mentioned above under compound IV and can be used for the treatment of angiogeneous diseases. Compositions comprise compounds of general formulars I, IV and V, alone or in combination.

The above mentioned compounds are also claimed matter within the inventive combinations.

[0023] A further example for ligand binding inhibitors are peptides and DNA sequences coding for such peptides, which are used for the treatment of angiogeneous diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59 of the sequence protocol. It has been shown that Seq. ID Nos. 34 and 34a are of main interest.

[0024] Claimed matter of the instant invention are therefor pharmaceutical compositions

a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

b) comprising one or several agents as compound I which are targeted to the endothelium via of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium,

d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of

the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,

g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

[0025] For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately.

[0026] The inventive compositions comprise as compound I or as compound II at least one of

- a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

These compositions are also claimed matter of the present invention.

[0027] Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

[0028] Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

[0029] The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.

Therefore, claimed matter of the present invention are also pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II, and most preferred pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35; pharmaceutical compositions, which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

[0030] The small molecule compounds, proteins and DNA's expressing proteins, as mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no scar formation before the axons communicate with each other. Therefore a reconstruction of the nerve bindings is much more easier.

[0031] Further, the inventive combinations can be used for suppression of the ascites formation in patients. It is also

possible to suppress VEGF oedemas.

For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch, magnesium stearate, talcum, plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.

If necessary, the compositions additionally contain additives, such as preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/ or buffer.

These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds

[0032] For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients thereof.

For oral application especially suitable are tablets, pills or capsules with talcum and/ or hydrocarbon carriers or binders, such as lactose, maize or potato starch. The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener.

The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg. The dosis can be applied as single dose or as two or more daily dosis.

[0033] These formulations and application forms are also part of the instant invention.

[0034] Combined functional interference with VEGFNFGF receptor systems and with Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to interference with one ligand/receptor system overlaps with the biological response to interference with a second ligand/receptor system. Alternatively, combined functional interference with VEGFNFGF receptor systems or with Angiopoietin/Tie receptor systems and targeting of cytotoxic agents via VEGFNFGF receptor systems or via Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to functional interference with a ligand/receptor system overlaps in time with targeting of cytotoxic agents.

[0035] The invention is also directed to a substance which functional interferes with both VEGFNFGF receptor systems and Angiopoietin/Tie receptor systems, or which are targeted via both VEGFNFGF receptor systems and Angiopoietin/Tie receptor systems.

[0036] VEGFNFGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C, VEGF-D, PlGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2 (KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1). Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor tyrosine kinases Tie1 and Tie2.

[0037] Pharmaceutical compositions of the present invention can be used for medicinal purposes. Such diseases are, for example, cancer, cancer metastasis, angiogenesis including retinopathy and psoriasis. Pharmaceutical compositions of the present invention can be applied orally, parenterally, or via gene therapeutic methods.

[0038] Therefor the present invention also concerns the use of pharmaceutical compositions for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

[0039] The following examples demonstrate the feasibility of the disclosed invention, without restricting the invention to the disclosed examples.

Example 1

[0040] Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

[0041] Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector (A375v/pCEP). Swiss *nu/nu* mice were s.c. injected with 1×10^6 transfected A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase

inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 1

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

[0042] Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm² (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or separate interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm² to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I + compound II, treatment group 4) delayed growth of the tumors to a size of approx. 250 mm² to 38 days. This result clearly demonstrates the superior effect of a combination of interference with the VEGF-ANGF receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.

Example 2

[0043] Combination of functional interference with the Angiopoietin/Tie2 receptor system and neutralization of VEGF-A is superior to separate modes of intervention in inhibition of tumor growth.

[0044] Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated twice weekly over a period of time of 4 weeks with intraperitoneal doses of 200 µg of the VEGF-A-neutralizing monoclonal antibody (mAb) 4301-42-35 (Schlaeppli et al., J. Cancer Res. Clin. Oncol. 125, 336-342, 1999). Various modes of treatment are described in Table 2. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 2

treatment group	mode of treatment	
	mAb 4301-42-35 (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

[0045] Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 2) without treatment (group 1). Tumors treated with the VEGF-A-neutralizing mAb 4301-42-35 (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and neutralizing of VEGF-A by means of the mAb 4301-42-35 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

[0046] The superior effect of a combination of neutralization of VEGF-A and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 3

[0047] Combination of functional interference with the Angiopoietin/Tie2 receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

[0048] Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) was expressed in E. coli and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound I were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 3. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 3

treatment group	mode of treatment	
	scFv-tTF conjugate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

[0049] Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 3) without treatment (group 1). Tumors treated with the coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound I, treatment group 2) grew to a volume of approx. 500 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 300 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-ANEGF receptor I complex and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to VEGF/VEGF receptor systems.

Example 4

[0050] Combination of functional interference with the VEGF/VEGF receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

[0051] Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals re-

ceiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of a single chain antibody (scFv) specifically recognizing the human VEGF-ANEGF receptor I complex (WO 99/19361) which was expressed in E. coli and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 4. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 4

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	scFv-tTF conjugate (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

[0052] Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 4) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound II, treatment group 3) grew to a volume of approx. 500 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 400 mm³ within 28 days.

[0053] The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the VEGFNEGF receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to Angiopoietin/Tie receptor systems.

Example 5

[0054] Combination of functional interference with the Angiopoietin/Tie2 receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to separate modes of intervention in inhibition of tumor growth.

[0055] Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A fusion protein (L19 scFv-tTF) consisting of L19 single chain antibody specifically recognizing the oncofoetal ED-B domain of fibronectin and the extracellular domain of tissue factor was expressed in E. coli as described by Nilsson et al. (Nat. Med., in press). Further, L19 scFv-tTF data have been represented by D. Neri and F. Nilsson (Meeting "Advances in the application of monoclonal antibodies in clinical oncology", Samos, Greece, 31. May-2. June 2000). When tumors reached a size of approx. 200 mm³ animals receiving compound I were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 5. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 5

treatment group	mode of treatment	
	L19 scFv-tTF (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

[0056] Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 5) without treatment (group 1). Tumors treated with the coagulation-inducing L19 scFv-tTF (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the endothelium with L19 scFv-tTF (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 6

[0057] Combination of functional interference with the VEGF/VEGF receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to separate modes of intervention in inhibition of tumor growth.

[0058] Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of L19 scFv-tTF fusion protein as described in example 5. When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 6. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 6

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	L19 scFv-tTF (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

[0059] Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure

6) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the coagulation-inducing L19 scFv-tTF targeted to the endothelium (compound II, treatment group 3) grew to a volume of approx. 450 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 200 mm³ within 28 days.

[0060] The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the VEGF/VEGF receptor system over separate modes of intervention is clearly shown.

Description of the figures

[0061]

Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of a specific tyrosine kinase inhibitor and with the Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1). The abbreviations have the following meaning:

mock, con. = treatment group 1
 mock+VEGF-A = treatment group 2
 sTIE2-c113 = treatment group 3
 sTIE2-c113+VEGF-A = treatment group 4

Fig. 2 shows the superior effect on tumor growth inhibition of combination of VEGF-neutralization and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 2).

Fig. 3 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 3).

Fig. 4 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 4).

Fig. 5 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 5).

Fig. 6 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 6).

Sequence Identifier

5 <110> Schering Aktiengesellschaft

<120> Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use II

10 <130> 51867AEPm1XX00-P

<140>
<141>

15 <160> 59

<210> 1
<211> 1835
<212> DNA
<213> Human

20 <400> 1

25	ttttacagtt	ttccttttct	tcagagttta	ttttgaattt	tcattttttgg	ataaccaagc	60
	agctctttta	gaagaatgca	cagaagagtc	attctggcac	ttttggatag	tacataagat	120
	tttctttttt	tttttttaaat	tttttttaaat	agtcacattc	agctcgcttg	ctcaaaccag	180
	actcccacat	tgggtgagca	agatgagccc	ataggattcc	agagttaata	cgtaaccgta	240
	tatacaaaaca	gccaaaaaac	cataatggtg	ccacagggat	ggagcagggg	agggcatctc	300
	taacgtgtcc	tctagtctat	cttcgctaaa	cagaacccac	gttacacatg	ataactagag	360
	agcacactgt	gttgaaacga	ggatgctgac	cccaaattggc	acttggcagc	atgcagttta	420
	aagcaaaaga	gacatccttt	aataactgta	taaaatccag	gcagttccat	taaaggggtt	480
30	aagaaaacca	acaacaacaa	aaagcgaggg	actgtctggt	gtcactgtca	aaaaggcact	540
	tggagttaat	gggaccagga	ttggaggact	cttagctgat	acagatttca	gtacgatttc	600
	attaaaaggc	ttggatgtta	agagaggaca	ctcagcgggt	cctgaagggg	gacgctgaga	660
	tggaccgctg	agaagcggaa	cagatgaaca	caaagggaatc	aaatctttac	aaccaaaattg	720
	catttaagcg	acaacaaaaa	aaggcaaaacc	ccaaaacgca	acctaaccac	agcaaaatct	780
	aagcaaaatc	agacaacgaa	gcagcgatgc	atagctttcc	tttgagagaa	cgcatacctt	840
35	gagacgctac	gtgccaacct	aagtctctca	cgacagcttc	acagtaggat	tattgtgata	900
	aaaatgactc	aagcgatgca	aaaagtttca	tctgttccca	gaatccgagg	gagaactgag	960
	gtgatcggtta	gagcatagcg	acatcacgtg	cggttttctta	atgtccctgg	tggcgggatac	1020
	gccgagtcct	cgaagggaca	tctggacacc	actttcagcc	acctccttgc	aggggcgcaca	1080
	tccgccaaag	tcatccttta	ttccgagtaa	taactttaat	tcctttctaa	catttacacg	1140
40	gcaaacagga	atgcagtaaa	cgtccacgtc	cgtcccacgg	ctgggctgcc	gttccgtttc	1200
	ctccacgaac	gggtacgcgc	ttccatgaga	aaggatattt	ggcaatttta	tattccacag	1260
	tcagggtgggt	ctgcgatagc	tcattttaatg	ttaaaccgca	tcaggggect	ctcctcccgt	1320
	ttctgccagg	ggcttttctt	gtcttctcct	tggcgagctc	gtgggcagat	cttctctgggt	1380
	gggggctggc	tgctggctcc	gagggggcat	ccgcagtcog	tctggctgct	tcctcctgca	1440
	ggctgggcag	ctggccacca	cttctccgac	tcgacccttc	caacaagcat	cgcagggcac	1500
45	tgtctctcgg	ggtacagacc	gtgggtcccac	attcgtacc	actctgttcc	acgtcatcca	1560
	ggtacacgag	ctgcgtgtag	gccgtgctgt	ctggggctcg	aggctctttc	tgctgggtgct	1620
	cttggaacggg	cgggtagttc	tgctgcagag	acaaagcatc	tccccctccc	ttccgggctg	1680
	attttggttc	attcatatct	acgccagagt	ccaaactggc	atcattactt	ccgttccttc	1740
	cagctctttg	gagaatcaat	gtatgaatgt	ctaacctgac	cgttggacct	gccatccaag	1800
50	gagacgaacc	acgcccgggg	gtgcggaagc	ggcct			

<210> 2
<211> 581
<212> DNA
<213> Human

55

EP 1 586 333 A2

<400> 2

5 gttctagatt gttttattca gtaattagct ctttaagaccc ctggggcctg tgctacccag 60
acactaacia cagtctctat ccagttgctg gttctgggtg acgtgatctc cccatcatga 120
tcaacttact tctgtgggcc cattaggga gtggtgacct cgggagctat ttgcctgttg 180
agtgcacaca cctggaaaca tactgctctc attttttcat ccacatcagt gagaaatgag 240
tggcccggtta gcaagatata actatgcaat catgcaacaa agctgcctaa taacatttca 300
tttattacag gactaaaagt tcattattgt ttgtaaagga tgaattcata acctctgcag 360
agttatagtt catacacagt tgatttccat ttataaaggc agaaagtcct tgttttctct 420
10 aaatgtcaag ctttgactga aaactcccgt ttttccagtc actggagtgt gtgcgtatga 480
aagaaaatct ttagcaatta gatgggagag aagggaata gtacttgaaa tgtaggcct 540
cacctcccca tgacatectc catgagcctc ctgatgtagt g

<210> 3

<211> 516

15 <212> DNA

<213> Human

<400> 3

20 tagagatggt ggttgatgac ccccgggatc tggagcagat gaatgaagag tctctggaag 60
tcagcccaga catgtgcatc tacatcacag aggacatgct catgtcgcgg aacctgaatg 120
gacactctgg gttgattgtg aaagaaattg ggtcttccac ctcgagctct tcagaaacag 180
ttgttaagct tcgtggccag agtactgatt ctcttcacac gactatatgt cggaaaccaa 240
agacctccac tgatcgacac agcttgagcc tcgatgacat cagactttac cagaaagact 300
tctgcgcat tgagggtctg tgtcaggaca ctgctcagag ttacaccttt ggatgtggcc 360
atgaactgga tgaggaaggc ctctattgca acagttgctt ggcccagcag tgcatcaaca 420
25 tocaagatgc ttttccagtc aaaagaacca gcaataactt ttctctggat ctcaatcatg 480
atgaagtcc agagtttgtt gtgtaaagtc cgtctg

<210> 4

<211> 1099

30 <212> DNA

<213> Human

<400> 4

35 cccacaacac agggggcctg aaacacgcca geectctctc tgtgggtcagc ttggcccagt 60
cctgctcact ggatcacagc ccattgtagg tggggcatgg tggggatcag ggcccctggc 120
ccacggggag gtagaagaag acctggtccg tgtaagggtc tgagaagggt ccctgggtcg 180
ggggtgcgtc ttggccttgc cgtgccctca tccccggct gaggcagcga cacagcaggt 240
gcaccaactc cagcaggtta agcaccagg agatgagtcc aaccaccaac atgaagatga 300
tgaagatggt cttctccgtg gggcgagaga caaagcagtc cagcaggtag gggcaggggtg 360
ctcgttgcca cacaacacag ggctccatgg tccagccgta caggcgccac tggccataga 420
ggaagcctgc ctctagcaca ctcttgacaga gcacactggc gacatagggt cccatcagtg 480
40 ctccgcggat gcgcaggcga ccactctctc ccaccgagat cttggccatc tgacgctcta 540
cgccgcgcag cgcccgctcc acctgtgggt ccttgggcgg cagtggccgc agctccccct 600
ccttctgccg cagccgctct tctcgccgag acaggtaaag gacatggccc aggtagacca 660
gggtgggtgt gctgacgaag aggaactgca gcacccagta gcggatgtgg gagatgggga 720
aggcctggtc atagcagacg ttggtgcagc ctggctgggc cgtgttacac tcgaaatctg 780
actgctcgtc accccacact gactcgccgg ccaggccag gatgaggatg cggaagatga 840
45 agagcaccgt cagccagatc ttaccacca cggctcagtg ctctggacc tggctccagca 900
acttctccac gaagccccag tcacccatgg ctcccgggcc tccgtcggca aggagacaga 960
gcacgtcagt gtgtcagcat ggcacctctc tcgttcgccc agcaacaagc ctgcagggag 1020
gtctgccacg ccggttctac cgctgcctg ccgggcggcc caggtggagg tggggacgat 1080
ggccggagtg acgcccgcg

<210> 5

<211> 1015

50 <212> DNA

<213> Human

<400> 5

55 gaggataggg agcctggggg caggagtgtg ggagacacag cgagactctg tctccaaaaa 60

EP 1 586 333 A2

5 aaaaagtgct ttttgaaaat gttgaggttg aaatgatggg aaccaacatt ctttggaattt 120
 agtggggagc ataatagcaa acacccccctt ggttcgcaca tgtacaggaa tgggacccag 180
 ttgggggcaca gccatggact tccccgcct ggaatgtgtg gtgcaaagtg gggccagggc 240
 ccagacccaa gaggagagg tgggtccgag acaccccg atgtcagcat cccccgacct 300
 gccttctggc ggcacctccc ggggtgctgtg ttgagtcagc aggcattggg tgagagcctg 360
 gtatatgctg ggaacagggt gcaggggcca agcgttcctc cttcagcctt gacttggggc 420
 atgcaccccc tctcccccaa acacaaacaa gcaattctcc agtatgggtg caggacaggt 480
 gtcccttcag tctctgtgtt atgacctcaa gtcctacttg ggccctgcag ccagcctgt 540
 gttgtaacct ctgcgtcttc aagaccacac ctggaagatt cttcttccct ttgaaggaga 600
 10 atcatcattg ttgctttatc acttctaaaga cattttgtac ggcacggaca agttaaacag 660
 aatgtgcttc cctccctggg gtctcacacg ctcccacgag aatgccacag gggccgtgca 720
 ctgggcaggc ttctctgtag aaccccaggg gctctggccc agaccacagc gtcttgccct 780
 gagcctagag cagggaagtc cgaacttctg cattcacaga ccacctccac aattgttata 840
 accaaaggcc tctgtttctg ttatttctact taaatcaaca tgctattttg ttttctactca 900
 cttctgactt tagcctcggtg ctgagccgtg tatccatgca gtcatgttca cgtgctagtt 960
 acgtttttct tcttacacat gaaaataaat gcataagtgt tagaagaaaa aaaaa
 15 <210> 6
 <211> 2313
 <212> DNA
 <213> Human
 20 <400> 6

 25 ccagagcagg cctggtgggtg agcagggagc gtgcaccgga cggcgggagc gagcaaatgg 60
 gtctggccat ggagcacgga gggctctacg ctcgggcggg gggcagctct cggggctgct 120
 ggtattacct gcgtacttct ttctctctcg tctccctcat ccaattctctc atcatcctgg 180
 ggctcgtgct ctcatgggtc tatggcaacg tgcacgtgag cacagagtcc aacctgcagg 240
 ccaccgagcg ccgagccgag ggctatatac gtcagctcct agggctcacg gcctcccagt 300
 ccaacttgac caaggagctc aacttcacca cccgcgccaa gcatgccatc atgcagatgt 360
 ggctgaatgc tcgcccgcgac ctggaccgca tcaatgccag cttccgccag tgccagggtg 420
 accgggtcat ctacacgaac aatcagagggt acatggctgc catcatcttg agtgagaagc 480
 aatgcagaga tcaattcaag gacatgaaca agagctgcga tgcttgctc ttcatgctga 540
 30 atcagaaggt gaagacgctg gagtgaggga tagccaagga gaagaccatt tgcactaagg 600
 ataaggaaa cgtgctgctg aacaaacgcg tggcgaggga acagctgggt gaatgcgtga 660
 aaaccgggga gctgcagcac caagagcgcc actggccaag gagcaactgc aaaagggtgca 720
 agccctctgc ctgcccctgg acaaggacaa gtttgagatg gaccttcgta acctgtggag 780
 ggaactccatt atcccacgca gcctggacaa cctgggttac aacctctacc atcccctggg 840
 ctcggaattg cctccatcc gcagagcctg cgaccacatg cccagcctca tgagctccaa 900
 ggtggaggag ctggcccggg gcctccgggc ggatatcgaa cgcgtggccc gcgagaactc 960
 35 agacctccaa cgcagaagc tggaaagcca gcagggcctg cgggccagtc aggaggcgaa 1020
 acagaaggtg gagaaggagg ctacggcccg ggaggccaag ctccaagctg aatgctcccg 1080
 gcagaccacg ctagcgtggtg aggagaaggc ggtgctgcgg aaggaaacgag acaacctggc 1140
 caaggagctg gaagagaaga agagggaggc ggagcagctc aggatggagc tggccatcag 1200
 aaactcagcc ctggacacct gcatcaagac caagtgcag ccgatgatgc cagtgtcaag 1260
 gcccattggc cctgtcccca acccccagcc catcgacca gctagcctgg aggagttcaa 1320
 40 gaggaagatc ctggagtccc agaggccccc tgcaggcatc cctgtagccc catccagtgg 1380
 ctgaggaggc tccaggcctg aggaccaagg gatggcccga ctcggcggtt tgcggaggat 1440
 gcagggatat gctcacagcg cccgacacaa cccctcccg ccgcccccaa ccacccaggg 1500
 ccaccatcag acaactocct gcatgcaaac ccctagtacc ctctcacacc cgcaaccgcg 1560
 cctcacgac cctcacccag agcacacggc cgcgagatg acgtcacgca agcaacggcg 1620
 ctgacgtcac atatcacctg ggtgatggcg tcacgtggcc atgtagacgt cacgaagaga 1680
 45 tatagcgatg gcgtcgtgca gatgcagcac gtgcacaca gacatgggga acttggcatg 1740
 acgtcacacc gagatgcagc aacgacgtca cgggccatgt cgacgtcaca catattaatg 1800
 tcacacagac gcggcgatgg catcacacag acggtgatga tgtcacacac agacacagtg 1860
 acaacacaca ccatgacaac gacacctata gatatggcac caacatcaca tgcaacgcatg 1920
 ccctttcaca cacactttct acccaattct cacctagtgt cacttcccc cgacctggc 1980
 acacgggcca aggtacccac aggatcccat cccctcccg acagccctgg gccccagcac 2040
 50 ctcccctcct ccagcttccct ggctcccag ccacttctc acccccagtg cctggacccg 2100
 gaggtgagaa caggaagcca ttacacctcg ctcttgagc gtgagtgtt ccaggacccc 2160
 ctcggggccc gtgagcgggg gtgaggtca cctgttctg ggaggggagc cactccttct 2220
 cccccaactc ccagccctgc ctgtggcccg ttgaaatgtt ggtggcactt aataaatatt 2280
 agtaaatcct taaaaaaaaa aaaaaaaaaa aaa
 55 <210> 7
 <211> 389

EP 1 586 333 A2

<212> DNA
<213> Human

<400> 7

5
gccccaaaaga tggcttcaaa agtaagaatg aaacatttga tccattcagc tttaggctat 60
gccactggat tcatgtctag aaaagatagg ataatttctg taaagaaatg aagaccttgc 120
tattctaaaaa tcagatcctt acagatccag atttcaggaa acaaatacat aggggactaa 180
ctttccttgt tcagattagt ttttctcctt tgcacccagc tatataatat gaggaagtat 240
tgactttttaa aaagtgtttt agttttccat ttctttgata tgaaaagtaa tatttcggga 300
10 gaacctgag ctattaataa tctatgtggc tagtgcgat atattggct gaatttgttc 360
tccttttgtg gtgtccagtg ggtaacatc

<210> 8
<211> 157
<212> DNA
15 <213> Human

<400> 8

tgcttttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt ggttttgtag 60
gaagcaggaa gcaagccac tcaaacgtga aatttggcat gagggatcca gtaactttct 120
20 cctcaatctg tgaactatat gtgagtttga tattttg

<210> 9
<211> 561
<212> DNA
25 <213> Human

<400> 9

aatagtcaaaa acataaaca aagctaatta actggcactg ttgtcacctg agactaagtg 60
gatgttggtg gctgacatac aggtcagcc agcagagaaa gaattctgaa tcccccttgc 120
30 tgaactgaac tattctgtta catatgggtg acaaactctgt gtgttatttc ttttctacct 180
accatattta aattttatgag tatcaacoga ggacatagtc aaaccttcga tgatgaacat 240
tctgtatttt ttgcctgatt aatctctgtt gagctctact tgtggtcatt caagatttta 300
tgatgttgaa aggaaaagtg aatatgacct ttaaaaattg tattttgggt gatgatagtc 360
tcaccactat aaaactgtca attattgact aatgttaaaag atatccatca ttgtgattaa 420
ttaaacctat aatgagtatt cttaatggag aattcttaat ggatggatta tccccctgatc 480
35 ttttctttta aattttctctg cacacacagg acttctcatt ttccaataaa tgggtgtact 540
ctgccccaat ttctagga a

<210> 10
<211> 1508
<212> DNA
40 <213> Human

<400> 10

cacaaacacg agagactcca cggctctgct gagcacgcgc agcctcctag gctccagcac 60
tcgcaggtcc attcttctgc acgagcctct ctgtccagat ccataagcac ggtcagctca 120
45 gggtcgcgga gcagtacgag gacaagtacc agcagcagct cctctgaaca gagactgcta 180
ggatcatcct tctcctccgg gctgttgcct gatggcataa tccgggtgca acccaaatct 240
gagctcaagc caggtgagct taagccactg agcaaggaag atttgggcct gcacgcctac 300
agggtgtgagg actgtggcaa gtgcaaatgt aaggagtgc cctacccaag gctctgccca 360
tcagactgga tctgcgacaa gcagtgcctt tgctcggccc agaacgtgat tgactatggg 420
acttgtgtat gctgtgtgaa aggtctcttc tatcactggt ctaatgatga tgaggacaac 480
50 tgtgctgaca acccatgttc ttgcagccag tctcactggt gtacacgatg gtcagccatg 540
gggtgcatgt cctctttttt gccttgttta tgggtttaac ttccagccaa ggggttgcctt 600
aaattgtgcc aggggtgtta tgaccgggtt aacaggcctg gttgccgctg taaaaactca 660
aacacagttt cgtgcaaaagt tcccactgtc cccctaggga actttgaaaa accaacatag 720
catcattaat caggaatat acagtaatga ggattttttt tttctttttt taatacacat 780
atgcaaccaa ctaaacagtt ataactcttg cactgttaat agaaagtgg gatagcttt 840
55 cctgtttgcg gtgaaatgct ttttgtccat gtgccgtttt aactgatatg cttgttagaa 900
ctcagctaag ggagctcaaa gtatgagata cagaacttgg tgacctatgt attgcataag 960
ctaaagcaac acagacactc ctaggcaaaag tttttgtttg tgaatagtac ttgcaaaact 1020

EP 1 586 333 A2

5 tgtaaattag cagatgactt ttttccattg ttttctccag agagaatgtg ctatatTTTT 1080
 gtatatataa taatatTTTgc aactgtgaaa aacaagtggg gccatactac atgggcacaga 1140
 cacaaaaatat tatactaata tggtgtacat tcggaagaat gtgaatcaat cagtatgttt 1200
 ttagattgta ttttgcctta cagaaagcct ttattgtaag actctgattt ccctttggac 1260
 ttcatgtata ttgtacagtt acagtaaaat tcaaccttta ttttctaatt ttttcaacat 1320
 attgttttagt gtaaagaata tttatttgaa gttttattat tttataaaaa agaataTTTta 1380
 ttttaagagg catcttataa attttgcccc ttttatgagg atgtgatagt tgctgcaaat 1440
 gaggggttac agatgcatat gtccaatata aaatagaaaa tatattaacg tttgaaatta 1500
 aaaaaaaaa

10 <210> 11
 <211> 389
 <212> DNA
 <213> Human

15 <400> 11

20 gggcagggtga tcagggcaca catttcccgt ccattgagac agtagcattc ccggcaccca 60
 tcgtgccagc tctctcatt tttatgatga tgaccatcca cggtgagaca agtgcccgcac 120
 aggatgggtg gccagctga agcacaggcc gctctgact tgcagataag acagccgtga 180
 ctgtctgtct ggaaacccaa ggggcagatc ttactgcatg agagctctgg acatttctta 240
 cagcgacaga tgtcacagcc gtgcttattc ttcagcaatc caagtggaca atacttgtca 300
 cagattatgg gtctgcactt cttgggcctt gggcggcact cacagatctc acagtttttg 360
 acctcgcccg cgaccacgct gggtaccga

25 <210> 12
 <211> 981
 <212> DNA
 <213> Human

30 <400> 12

35 tttttttttt ttggattgca aaaatttatt aaaattggag acactgtttt aatcttcttg 60
 tgccatgaga ctccatcagg cagtctacaa agaccactgg gaggtgagg atcacttgag 120
 occagaagtt tgaggctgta gtaagcttca aaggccactg cactctagct tgggtgaggc 180
 aagacccttt caagcagtaa gctgcatgct tgcttgttgt ggtcattaaa aaccctagtt 240
 taggataaca acatattaat cagggcacaaa tacaatgtg tgatgcttgt tagtagagta 300
 acctcagaat caaaatggaa cggttttaca gtgatcatat tatatttcat ttggcagaat 360
 cattacatca ttggttacac tgaaaatcat cacatgtacc aaaagctgac tcacctagtt 420
 taggataaca ggtctgcctg tttgaagatg aaaaaataa cccattttaa atttgcccta 480
 ctcaatttcc ttctcagtc ctttttaact tttaaacagc taatcactcc catctacaga 540
 ttaagggtgta tatgccacca aaaccttttg ccaccttaaa aatttccttc aaagttttaa 600
 ctaatgcctg catttcttca atcatgaatt ctgagtcctt tgcttcttta aaacttgctc 660
 cacacagtgt agtcaagccg actctccata cccaagcaag tcatccatgg ataaaaacgt 720
 taccaggagc agaaccatta agctgggtcca ggcaagttgg actccaccat ttcaacttcc 780
 agctttctgt ctaatgcctg tgtgccaatg gcttgagtta ggcttgctct ttaggacttc 840
 40 agtagctatt ctcatccttc cttggggaca caactgtcca taaggtgcta tccagagcca 900
 cactgcatct gcaccagca ccatacctca caggagtcca ctcccacgag ccgcctgtat 960
 ataagagttc ttttgatgac g

45 <210> 13
 <211> 401
 <212> DNA
 <213> Human

50 <400> 13

55 ataactacag cttcagcaga caactaaaga gactgcatta aggtgatttc tctggctata 60
 aagagagccc ggcgcagag catgtgactg ctgggacctc tgggataggc aacactgccc 120
 tctctcccc agagcgaccc cccgggcagg tcggggccca aggaatgacc cagcaactgc 180
 tccctaccca gcacactctc ttactgcca cctgcaatta tgctgtgaag atgactgggt 240
 gtggtcacat cgattcagag aaatcaagat ctatgaccat tttaggcaaa gagagaaact 300
 tggagaattg ctgaggacta ctgaaccttg ttttgctttt ttaaaaaata ctaaattcctc 360
 acttcagcat atttagttgt cattaaattt aagctgatat t

<210> 14

EP 1 586 333 A2

<211> 1002
<212> DNA
<213> Human

5 <400> 14

```

gacaatataa aaagtggaaa caagcataaa ttgcagacat aaaataatct tctggtagaa 60
acagttgtgg agaacagggt gagtagagca acaacaacaa aagccttatgc agtcaccttc 120
tttgaaaatg tttaatacaa gtctatttct ctttgtccag ctgggttttag ctagaggtag 180
ccaattactt ctcttaaggt ccatggcatt cgccaggatt ctataaaaagc caagttaact 240
gaagtaaata tctggggccc atcgaccccc cactaagtac tttgtcacca tgttgatatct 300
taaaagtcac ttttccactgt ttgactcaga atttgggact tcagagtcaa acttcattgc 360
ttactccaaa ccaggtttaa ttccccactt ttttaagtag gcttagcttt gagtgatttt 420
tggctataac cgaaatgtaa atccaccttc aaacaacaaa gtttgacaag actgaaatgt 480
tactgaaaac aatgggtgcc tatgtctcaa agacatttcc ccaagataac tgccaaagag 540
tttttgagga ggacaatgat cattttattat gtagtaacca agcctttctg cccaggaagt aacaaacatc 600
attaatacag ctcaaatgga gtagtaacca agcctttctg cccaggaagt aacaaacatc 660
actacgaaca tgagagtaca agaggaaact ttcataatgc attttttcat tcatacatc 720
attcaataaa cattagccaa gctaattgtc caagccactg tgccaggtag taacaatata 780
acaacaataa aagacacagt ccttcctctc aagggtgttc gtctagtagg gaagatgatt 840
attcattaaa atttttgggt catcagaatc atgaggagct tgtcaaaaat gtaaatcct 900
gcctatgttc tcagatattc tggttaggtc aggagtggga acccaaaatc aattctttta 960
acaaacacta aaggtgattc taacacaggc ggtgtgagga cc

```

<210> 15
<211> 280
<212> DNA
<213> Human

25 <400> 15

```

cgaggtgggc caccctgtgc tggctctgaga tttttaaatg aggattacat taccctatct 60
ataatattcc tattcctaac tattgtattc ttacaattaa atgtatcaaa taattcctta 120
aaacattatt agaaacaaac tgccataatc cttataagac taaaaaaatc accaagatga 180
aactgtatta tgactctcaa tattttaaaca tttaaaaaaa tgttagtggt tgtaaagcac 240
caatcttaac tatttcacct gcccgggcgg ccgctcgagg

```

<210> 16
<211> 2041
<212> DNA
<213> Human

35 <400> 16

```

ccccccgcag aactcccccc tggaaatagga tttttaaaac ccttgacaat tagaaatcct 60
atagagggtta gcattttttta ggtaaaaata tgggtgcccc tacagggatc atgcaacttc 120
cttaaaaacca attcagcaca tatgtataaa gaaccctttt taaaaacatt tgtacttgaa 180
atacagacac agtgatgctg aagacactaa acaaaaactg aaaagtacta taccttgata 240
aattttgtta ttgccttctt tagagacttt ataactctca gttgattttc aaggacttga 300
atttaataat ggggtaatta cacaagacgt aaaggatttt taaaaaaca gtattttttt 360
ttacctctag catcaattct tttataaaga atgctaaata aattacattt tttgttcagt 420
aaaactgaag atagaccatt taaatgcttc taccaaattt aacgcagctt aattagggac 480
caggtacata ttttctctctg aacatttttg gtcaagcatg tctaaccata aaagcaaatg 540
gaattttaag aggtagattt tttttccatg atgcattttg ttaataaatg tgtcaagaaa 600
ataaaaacaa gcactgagtg tgttctcttg aagtataagg gtctaataaa aaataaaaaga 660
tagatatttg ttatagctctg acatttttaac agtcatagta ttagacgttt cgtgaccagt 720
gcatttttga ctctctcagg atcaaaaatac gactctgcca actgtattaa atcctcctcc 780
acccctcca ccagttgggtc cacagcttcc tgggtgggtcg ttgtcatcaa atccattggg 840
ccgaaatgaa catgaagcag atgcagcttg gaggcccggt gctcgagcat tcaactcttg 900
ttcctgtaaa tatagtttat tgtcttttgt tatagcatcc ataagttctt tctgtagagg 960
tgggtctcca ttatccaga gtccactggt tgggttatta ccacttaaac cattagtagt 1020
atgctgtttt ttatacaaaa gcacataagc tgtgtccttt ggaaacctgc tcgtaatttt 1080
ctggactgac tgaaatgaag taaatgtcac tctactgtca ttaataaaaa acccattctt 1140
ttgacatttc cttattttcc aaatcctggt caaaaactgc actgggacta tctctcccta 1200
gtaaatgact ctgggaggat gtaaatgcca gagcctcaga ctgggtggtag atctgatatg 1260
aagagtctgt acttgtgata tttctggcat aagaatagta atgccactt tcagaggata 1320

```

EP 1 586 333 A2

	taccagagtg	aaccacaacg	gaacttaata	gatagggcac	caattttgtg	caggaagctt	1380
	catcagtocc	tgaaggcttt	aatttttttag	caagggttctc	actaagatca	gtgaagtcaa	1440
	catctacaga	ccaactttct	gacaatgaag	agaaagaagt	aattcttcta	actggcaact	1500
	ccaaaaccag	tggccagtga	tacattgtct	aaaattttcc	ttctcacatg	atacttctga	1560
5	tcatatgaaa	atctcaggag	agtaagaata	aggtattcag	gttcctccgt	gatttgcata	1620
	gttttctcag	cattttgcag	agaggcacag	ttttcacaa	aatattgggt	atcaccagta	1680
	agaatctctg	gagcccaaaa	aataatttag	taagtcagtt	actgaagggt	tggtttcacc	1740
	tcccggtttc	tgaggtagat	ctttattaac	aagaatcttg	ttagattcgt	tagggacaga	1800
	agtgttttca	gaacagtaaa	actcattagg	aggactgcct	atggtttttt	cattcacaag	1860
	tgagtcacag	atgaaggcag	ctgttggttg	attataaaact	actggctctt	ctgaaggacc	1920
10	gggtacagac	gcttgcat	gaccaccatc	ttgtatactg	gggtgatgat	ctggatcttg	1980
	gacagacatg	ttttccaaag	aagaggaagc	acaaaacgca	agcgaaagat	ctgtaaaggc	2040
	t						
	<210>	17					
	<211>	235					
15	<212>	DNA					
	<213>	Human					
	<400>	17					
	cgccccgggc	aggtgtcagg	ggttccaaac	cagcctgggg	aaacacagcg	tagacccttc	60
20	acctctacaa	ataaaaaatt	aaaaaatttag	ccagggtgtg	cagcgaacaa	ctgtagtctc	120
	agataactcag	gagactgagc	tggaaaggat	cacttgagcc	caagaagttc	aagggttacag	180
	tgggccacga	tcatgtcatt	acactccagc	ttgggtgaca	aaatgagact	gtcta	
	<210>	18					
	<211>	2732					
25	<212>	DNA					
	<213>	Human					
	<400>	18					
	gtgtggagtt	tcagctgcta	ttgactataa	gagctatgga	acagaaaaag	cttgtctggct	60
30	tcatgtttgat	aactacttta	tatggagctt	cattggacct	gttaccttca	ttattctgct	120
	aaatattatc	ttcttgggtga	tcacattgtg	caaaatgggt	aagcattcaa	acactttgaa	180
	accagattct	agcagggttg	aaaacattaa	gtcttgggtg	cttggcgctt	tcgctcttct	240
	gtgtcttctt	ggcctcacct	ggctcttttg	gttgcctttt	attaatgagg	agactattgt	300
	gatggcatat	ctcttcacta	tatttaatgc	tttccaggga	gtgttcattt	tcacttttca	360
	ctgtgctctc	caaaaagaaag	tacgaaaaga	atatggcaag	tgcttcagac	actcatactg	420
35	ctgtggaggc	ctcccaactg	agagtcccca	cagttcagtg	aaggcatcaa	ccaccagaac	480
	cagtgcctcg	tattcctctg	gcacacagag	tcgtataaga	agaatgtgga	atgatactgt	540
	gagaaaacaa	tcagaatctt	cttttatctc	aggtgacatc	aatagcactt	caacacttaa	600
	tcaaggtggc	ataaatctta	atatattatt	acaggactga	catcacatgg	tctgagagcc	660
	catcttcaag	atttatatca	tttagaggac	attcactgaa	caatgccagg	gatacaagtg	720
40	ccatggatac	tctaccgcta	aatggtaatt	ttaacaacag	ctactcgctg	cacaagggtg	780
	actataatga	cagcgtgcaa	gttgtggact	gtggactaag	tctgaatgat	actgcttttg	840
	agaaaatgat	catttcagaa	ttagtgcaca	acaacttacg	gggcagcagc	aagactcaca	900
	acctcgagct	cacgctacca	gtcaaacctg	tgattggagg	tagcagcagt	gaagatgatg	960
	ctattgtggc	agatgcttca	tctttaatgc	acagcgacaa	cccagggtcg	gagctccatc	1020
	acaaagaact	cgaggcacca	cttattcctc	agcggactca	ctcccttctg	taccaacccc	1080
45	agaagaaagt	gaagtccgag	ggaactgaca	gctatgtctc	ccaactgaca	gcagagggtg	1140
	aagatcacct	acagtccccc	aacagagact	ctctttatag	aagcatgccc	aatcttagag	1200
	actctcccta	tccggagagc	agccctgaca	tggagaaga	cctctctccc	tccaggaggga	1260
	gtgagaatga	ggacattttac	tataaaagca	tgccaaatct	tggagctggc	catcagcttc	1320
	agatgtgcta	ccagatcagc	aggggcaata	gtgatggtta	tataatcccc	attaacaaag	1380
	aagggtgtat	tccagaagga	gatgttagag	aaggacaaat	gcagctggtt	acaagctctt	1440
	aatcatacag	ctaaggaatt	ccaagggccca	catgcgagta	tttaataaata	aagacaccat	1500
50	tggcctgacg	caagctccctc	aaactctgct	tgaagagatg	actcttgacc	tgtgggtctc	1560
	tgggtgtaaaa	aagatgactg	aaccttgcat	ttctgtgaat	ttttataaaa	catacaaaaa	1620
	ctttgttatat	acacagagta	tactaaagtg	aattatttgt	tacaaaagaa	agagatgcca	1680
	gccagggtatt	ttaagattct	gctgctgttt	agagaaattg	tgaacaaagc	aaaacaaaac	1740
	tttccagcca	ttttactgca	gcagtctgtg	aactaaattt	gtaaatatgg	ctgcaccatt	1800
	tttgtaggcc	tgcattgtat	tatatacaag	acgtaggctt	taaaatcctg	tgggacaaat	1860
55	ttactgtacc	ttactattcc	tgacaagact	tggaaaagca	ggagagatat	tctgcatcag	1920
	tttgcagttc	actgc aaatc	ttttacatta	aggcaaaagat	tgaaaacatg	cttaaccact	1980

EP 1 586 333 A2

agcaatcaag ccacaggcct tatttcatat gtttcctcaa ctgtacaatg aactattctc 2040
 atgaaaaatg gctaaagaaa ttatatatttg ttctattgct agggtaaaat aaatacattt 2100
 gtgtccaact gaaatataat tgtcattaaa ataattttta agagtgaaga aaatattgtg 2160
 5 aaaaagctctt gggtgcacat gttatgaaat gttttttctt acactttgtc atggtaagtt 2220
 ctactcatit tcacttcttt tccactgtat acagtgttct gctttgacaa agttagtctt 2280
 tattacttac atttaaatit cttatttgcca aaagaacgtg ttttatgggg agaaacaaac 2340
 tctttgaagc cagttatgtc atgccttgca caaagtgat gaaatctaga aaagattgtg 2400
 tgtcaccctt gtttattctt gaacagaggg caaagagggc actgggcact tctcacaac 2460
 tttctagtga acaaaagggtg cctattcttt tttaaaaaaa taaaataaaa cataaatatt 2520
 10 actcttccat attccttctg cctatatatta gtaattaatt tattttatga taaagttcta 2580
 atgaaatgta aattgtttca gcaaaattct gctttttttt catccctttg tgtaaacctg 2640
 ttaataatga gcccatcact aatatccagt gtaaagttta acacggtttg acagtaaata 2700
 aatgtgaatt ttttcaagtt aaaaaaaaaa aa

 <210> 19
 <211> 276
 15 <212> DNA
 <213> Human

 <400> 19

 ctccctaaat gatttttaaaa taaattggat aaacatatga tataaagtgg gtactttaga 60
 20 aaccgccttt gcatattttt tatgtacaaa tctttgtata caattccgat gttccttata 120
 tattccctat atagcaaaacc aaaaccagga cctcccaact gcatgcctca agtccctgtg 180
 gagcactctg gcaactggat ggccctactt gctttctgac aaaatagctg gaaaggagga 240
 gggaccaatt aaatacctcg gccgcgacca cgctgg

 <210> 20
 25 <211> 2361
 <212> DNA
 <213> Human

 <400> 20

 attgtaccag ccttgatgaa cgtggggcct gcttcgcttt tgaggggccat aagctcattg 60
 30 cccactgggt tagaggctac cttatcattg tctcccgta ccggaagggt tctcccaagt 120
 cagagtttac cagcagggat tcacagagct ccgacaagca gattctaaac atctatgacc 180
 tgtgcaacaa gttcatagcc tatagcaccg tctttgagga tgtagtggat gtgcttgctg 240
 agtggggctc cctgtacgtg ctgacgcggg atggggcggg ccacgcactg caggagaagg 300
 35 acacacagac caaactggag atgctgttta agaagaacct atttgagatg gcgattaaac 360
 ttgccaagag ccagcatctg gacagtgatg ggctggccca gattttcatg cagtatggag 420
 accatctcta cagcaagggc aaccacgatg gggctgtcca gcaatatatc cgaaccattg 480
 gaaagtggga gccatcctac gtgatccgca agtttctgga tgcccagcgc attcacaacc 540
 tgactgccta cctgcagacc ctgcaccgac aatccctggc caatgccgac cataccacc 600
 tgctcctcaa ctgctatacc aagctcaagg acagctcgaa gctggaggag ttcatacaaga 660
 40 aaaagagtga gagtgaagtc cactttgatg tggagacagc catcaagggt ctcgggcagg 720
 ctggctacta ctcccatgcc ctgtatctgg cggagaacca tgcacatcat gagtgggtacc 780
 tgaagatcca gctagaagac attaagaatt atcaggaagc ccttcgatac atcggcaagc 840
 tgcttttga gcaggcagag agcaacatga agcgtacgg caagatcctc atgcaccaca 900
 taccagagca gacaactcag ttgctgaagg gactttgtac tgattatcgg cccagcctcg 960
 aaggccgcag cgataggag gccccaggct gcagggccaa ctctgaggag ttcatcccca 1020
 45 tctttgccaa taaccgcgga gagctgaaag ccttcctaga gcacatgagt gaagtgcagc 1080
 cagactcacc ccaggggatc tacgacacac tcttgagct gcgactgcag aactggggcc 1140
 acgagaagga tccacaggtc aaagagaagc ttcacgcaga ggccatttcc ctgctgaaga 1200
 gtggtcgctt ctgcgacgtc tttgacaagg ccctggctct gtgccagatg cagcacttcc 1260
 aggatgggtg cctttacctt tatgagcagg ggaagctgtt ccagcagatc atgcactacc 1320
 acatgcagca cgagcagtac cggcaggtca tcaagctgtg tgagcgccat ggggagcagg 1380
 50 acccctcctt gtgggagcag gccctcagct acttcgctcg caaggaggag gactgcaagg 1440
 agtatgtggc agctgtctc aagcatatcg agaacaagaa cctcatgccca cctcttctag 1500
 tgggtgcagac cctggccac aactccacag ccacactctc cgtcatcagg gactacctgg 1560
 tccaaaaact acagaaacag agccagcaga ttgcacagga tgagctgcgg gtgcggcggg 1620
 accgagagga gaccaccgt atccgccagg agatccaaga gctcaaggcc agtcctaaga 1680
 ttttccaaaa gaccaagtgc agcatctgta acagtgcctt ggagttgccc tcagtccact 1740
 55 tctgtgtgtg ccactcctc caccaacact gctttgagag ttactcgaa agtgatgctg 1800
 actgccccac ctgcctccct gaaaaccgga aggtcatgga tatgatccgg gcccggaac 1860
 agaaaacgaga tctccatgat caattccagc atcagctcaa gtgctccaat gacagctttt 1920

EP 1 586 333 A2

ctgtgattgc tgactacttt ggcagaggtg ttttcaacaa attgactctg ctgaccgacc 1980
 ctcccacagc cagactgacc tccagcctgg aggctgggct gcaacgcgac ctactcatgc 2040
 actccaggag gggcacttaa gcagcctgga ggaagatgtg ggcaacagtg gaggaccaag 2100
 5 agaacagaca caatgggacc tgggcgggcg ttacacagaa ggctggctga catgccagg 2160
 gctccactct catctaagt cagagccctc acaagactaa agcggaactt tttcttttcc 2220
 ctggccttcc ttaattttaa gtcaagcttg gcaatccctt cctctttaac taggcagggtg 2280
 ttagaatcat ttccagatta atggggggga aggggaacct caggcaaacc tcctgaagtt 2340
 ttgaaaaaaa aagctggttt c

 <210> 21
 10 <211> 179
 <212> DNA
 <213> Human

 <400> 21

 15 aggtgttaga tgctcttgaa aaagaaactg catctaagct gtcagaaatg gattctttta 60
 acaatcaact aaaggaactg agagaaacct acaacacaca gcagttagcc cttgaacagc 120
 tttataagat caacgtgaca agttgaagga aattgaaagg aaaaaattag aactaatgc

 <210> 22
 <211> 905
 20 <212> DNA
 <213> Human

 <400> 22

 25 tttttttttt ttctttaacc gtgtggtctt tatttcagt ccagtgttac agatacaaca 60
 caaatgttcc agttagaagg aattcaaacg gaatgccaa gccaagcca ggctcaagaa 120
 ataaaaagg aggtttggag taatagataa gatgactcca atactcactc ttctaaggg 180
 caaaggctact ttgtatcac agtctgatct ttgaaactg tgaactcctc ttccaccat 240
 taccatagtt caaacaggca agttatgggc ttaggagcac tttaaaattt gtgggtggaa 300
 tagggctcatt aataactatg aatatactt ttagaagggt accattttgc actttaaagg 360
 30 gaatcaattt tgaaaatcat ggagactatt catgactaca gctaaagaat ggcgagaaag 420
 gggagctgga agagccttgg aagtttctat tacaatatga gcaccatata cttcatgcca 480
 aatctcaaca aaagctctt ttaactccat ctgtccagt tttacaaata aactcgcaag 540
 gtctgaccag ttcttggtaa caaacatata tgtgtgtgtc tgtgtgtata cagcaatgca 600
 cagaaaaggc taccaggagc ctaatgcctc tttcaaacat tgggggaacc agtagaaaaa 660
 ggcagggctc cctaatgtcc attattacat ttccattccg aatgccagat gttaaaagt 720
 ctggaagatg gtaaccagc tagtgaggaa taaatacccc accttgccca gtccacagag 780
 35 aaacaacagt agaaagaagg ggcaactctt tgctgcagag acaaagttag tgttttttcg 840
 ccatggattg cagtctctc ctccagacca gctgcttatt tcctcagggg ccaggggaat 900
 gttga

 <210> 23
 <211> 2134
 40 <212> DNA
 <213> Human

 <400> 23

 45 ggtctcttct ttctttttt tttttccaaa agtggtcttt tatttctagt aacatatatt 60
 gtataaatac tctattttat atgcacttcc acaaaagcga tataatttaa aagttttttt 120
 cattagaaat aaatgtataa aaataaatat gttattatag gcatttatta ctaactatag 180
 tccttcttgg aaggaacacc caaaccaata cttataaagt acatgtaatt tatagtaaca 240
 tattttacta tatacatatg gaaaaaatca tattctcaca gaagagctga acagacattc 300
 accaggatac gactgttgga ccagctgctg gagatggacc tgctaccctc cagcagcctc 360
 cccaccacaa gacaagtgat ctcaatgtcc ccaaacctgt gggaccctgt tctacacacc 420
 50 tcatttttct tccggcggtt catctctctt gtgtgattgt actgattttc atgagacaca 480
 agttacttct ttacatccat attcccaaag cagggttaca tggtaggaaa gaaaggaagt 540
 tggaggtact aagctcattg tgtctctct agcttttacc agcatctaag gcttcactgc 600
 tttttttcca ttgtagactt taatgcactt gaataaatac atggagttgt tttttctca 660
 aaatgaatta cacaaataaa gactgagatg gtccaaaaaa ggaaagagga agccattttgc 720
 gttattttcac gttgctgagc ctttctctca tgttgaacaa tctgaagttt taattctcgg 780
 55 tagaataat gtataaacat tctctgaaac catagcagcc ataaacagt ctgggtcaaag 840
 atcctatttg tactcctttc tccccccatt gttagttagg taaagtaaaa cagggtcttag 900

EP 1 586 333 A2

5 taaaatctca cttttctcct acttttcatt tcccaacccc catgatacta agtattttgat 960
 aagtaccagg aaacaggggt tgtaatagtt ctaacttttt ttgacaattg cttttgttttt 1020
 tctaaacttg taatagatgt aacaaaagaa ataataataa taatgcccgg ggctttatta 1080
 tgctatatca ctgctcagag gttaataatc ctcactaact atoctatcaa atttgcaact 1140
 10 ggcagttttac tctgatgatt caactccttt tctatctacc ccataaatcc cacttacttg 1200
 atacacctca ctggttactg gcaagatacg ctggatccct ccagccttct tgctttccct 1260
 gcaccagccc ttctcactt tgccctgccc tcaaagctaa caccacttaa accacttaac 1320
 tgcattctgc cattgtgcaa aagtctatga aatgttttagg tttcttttaa ggatcacagc 1380
 tctcatgaga taacacccct ccatcatggg acagacactt caagcttctt tttttgtaac 1440
 ccttoccaca ggtcttagaa catgatgacc actccccag ctgccactgg gggcagggat 1500
 15 ggtctgcaca aggtctgggt ctggctgggt tcaacttcct tgccactcg gaagcaggct 1560
 gtccattaat gctctggcat tctaccagtc ttctctgcca acccaattca catgacttag 1620
 aacattcgcc ccaactctca atgacctatg ctgaaaaagt ggggatagca ttgaaagatt 1680
 ccttcttctt ctttacgaag taggtgtatt taatttttagg tgcgaaggga ttgccacag 1740
 taagaacctg gatgggtcaag ggctctttga gagggctaaa gctgcgaatt ctttccaatg 1800
 20 ccgcagagga gccgctgtac ctcaagacaa cacttttgta cataatgtct tgctctaagg 1860
 tggacaaaagt gtatgcacca ttaagaatat atgtgccatc agcagctttg atggcaagaa 1920
 agctgccatt gttcctggat cccctctggg tccgctgttt caactcgatg ttgggtggctc 1980
 cagttggaat tggatgata tcatgatata caggttttgc actagtaact gatcctgata 2040
 tttttttaca agtagatcca tttccccgc aaacaccaca tttatcaaac ttcttttttg 2100
 agtctatgat gcgatcacia ccagctttta caca
 25 <210> 24
 <211> 1626
 <212> DNA
 <213> Human
 <400> 24
 30 ggacaatttc tagaatctat agtagtatca ggatatattt tgcttttaaaa tatatttttg 60
 ttattttgaa tacagacatt ggctccaaat ttctatcttt gcacaatagt atgacttttc 120
 actagaactt ctcaacattt gggaactttg caaatatgag catcatatgt gttaaggctg 180
 tatcatttaa tgctatgaga tacattgttt tctccctatg ccaaacaggt gaacaaacgt 240
 agttgttttt tactgatact aaatgttggc taccctgtgat tttatagtat gcacatgtca 300
 gaaaaaggca agacaaatgg cctcttgtag tgaatacttc ggcaaaacta ttgggtcttc 360
 attttctgac agacaggatt tgactcaata tttgtagagc ttgcgtagaa tggattacat 420
 ggtagtgtat cactggtaga aatgggtttt agttattgac tcagaattca tctcaggatg 480
 aatcttttat gtctttttat tghtaagcata tctgaattta ctttataaaag atgggttttag 540
 aaagctttgt ctaaaaattt ggctaggaa tggtaacttc attttcagtt gccaaagggt 600
 agaaaaataa tatgtgtgtt gttatgttta ttttaacata ttattaggta ctatctatga 660
 35 atgtatttaa atatttttca tttctgtgta caagcattta taatttgcaa caagtggagt 720
 ccatttagcc cagtgggaaa gtcttggaac tcaggttacc cttgaaggat atgctggcag 780
 ccactctctt gatctgtgct taaactgtaa tttatagacc agctaaatcc ctaacttgga 840
 tctggaatgc attagttagt ccttgtagca ttcccagaat ttcaggggca tcgtgggttt 900
 ggtctagtga ttgaaaacac aagaacagag agatccagct gaaaaagagt gatcctcaat 960
 40 atcctaacta actggctctc aactcaagca gagtttcttc actctggcac tgtgatcatg 1020
 aaacttagta gaggggattg tgtgtatttt atacaaattt aatacaatgt cttacattga 1080
 taaaattctt aaagagcaaa actgcatttt atttctgcat ccacattcca atcatattag 1140
 aactaagata tttatctatg aagatataaa tgggtcagag agactttcat ctgtggattg 1200
 cgttgtttct tagggttcct agcactgatg cctgcacaag catgtgatat gtgaaataaa 1260
 atggattctt ctatagctaa atgagttccc tctggggaga gttctggtag tgcaatcaca 1320
 45 atgccagatg gtgtttatgg gctattttgt taagtaagtg gtaagatgct atgaagtaag 1380
 tgtgtttgtt ttcatcttat ggaaactctt gatgcatgtg cttttgtatg gaataaattt 1440
 tgggtgcaata tgatgtcatt caactttgca ttgaattgaa ttttggttgt atttatatgt 1500
 attataacct tcacgcttct agttgcttca accattttat aaccattttt gtacatatat 1560
 tacttgaaaa tatttttaaat ggaaatttaa ataaacattt gatagtttac ataataaaaa 1620
 aaaaaa
 50 <210> 25
 <211> 1420
 <212> DNA
 <213> Human
 <400> 25
 55 gttcagcatt gtttctgctt ctgaaatctg tatagtacac tggtttgtaa tcattatgtc 60

EP 1 586 333 A2

5 ttcattgaaa tccttgctac ttctcttcc cctcaatgaa agacacgaga gacaagagcg 120
 acacaagctt aagaaaaacg agcaaggaag agtatcttca ttattctcat tttctctgag 180
 ttggaacaaa aaacatgaag gactccaact agaagacaga tattttacatt taaatagatt 240
 agtgggaaaa ctttaagagt ttccacatat tagttttcat tttttgagtc aagagactgc 300
 tccttgtagt gggagacact agtagtatat gtttgtaatg ttactttaaa attatctttt 360
 tattttataa ggcccataaa tactggttaa actctgttaa aagtgggcct tctatcttgg 420
 atggtttcac tgccatcagc catgctgata tattagaaat ggcaccccta tctacttact 480
 ttaatgctta aaattatata taaaatgcct tatttagaaa acctacatga tacagtgggtg 540
 tcagccttgc catgtatcag tttcacttga aatttgagac caattaaatt tcaactgttt 600
 aggggtggaga aagaggtact ggaaaacatg cagatgagga tatcttttat gtgcaacagt 660
 10 atcctttgca tgggaggaga gttactcttg aaaggcaggc agcttaagtg gacaatgttt 720
 tgtatatagt tgagaatttt acgacacttt taaaaattgt gtaattgtta aatgtccagt 780
 tttgctctgt tttgcctgaa gttttagtat ttgttttcta ggtggacctc tgaaaaccaa 840
 accagtacct ggggaggtta gatgtgtgtt tcaggccttg agtgtatgag tggttttgct 900
 tgtattttcc tccagagatt ttgaacttta ataattgcgt gtgtgttttt ttttttttaa 960
 gtggctttgt ttttttttct caagtaaaat tgtgaacata tttcctttat aggggcaggg 1020
 15 catgagttag ggagactgaa gagtattgta gactgtacat gtgccttctt aatgtgtttc 1080
 tcgacacatt ttttttcagt aacttgaaaa ttcaaaaggg acatttggtt aggttactgt 1140
 acatcaatct atgcataaat ggcagcttgt tttcttgagc cactgtctaa attttgtttt 1200
 tatagaaatt ttttatactg attggttcat agatggtcag ttttgtagac agactgaaca 1260
 atacagcact ttgccccaaa tgagtgtagc attgttttaa cattgtgtgt taacacctgt 1320
 20 tctttgtaat tgggttgtgg tgcattttgc actacctgga gttacagttt tcaatctgtc 1380
 agtaataaaa gtgtccttta acttcaaaaa aaaaaaaaaa

<210> 26
 <211> 689
 <212> DNA
 <213> Human

<400> 26

30 aaacaaacaa aaaaaaagtt agtactgtat atgtaaatac tagcttttca atgtgctata 60
 caaacaatta tagcacatoc ttccctttac tctgtctcac ctcccttagg tgaagtacttc 120
 cttaaataag tgctaaacat acatatacgg aacttgaaag ctttggttag ccttgcccta 180
 ggtaatcagc ctagtttaca ctgtttccag ggagtagttg aattactata aaccattagc 240
 cacttgtctc tgcaccattt atcacaccag gacagggtct ctcaacctgg gcgctactgt 300
 catttggggc caggtgattc ttcccttgcaa gggctgtcct gtacctgcc gggcggcgcg 360
 tcgaagcgtg gtccgcgccg aggtactgaa aggaccaagg agctctggct gccctcagga 420
 attccaaatg accgaaggaa caaagcttca gggctctggg tgggtgtctc cactattcag 480
 35 gaggtgggtc aggtaaacgc agcttcattt cgctccagtc tttccagtat ttaaagttgt 540
 tgtaaatgat ctgcattaaa tcaggcaggt ctacaaaggc atcccaagca tcaaacatgt 600
 ctgtgatgaa gtaatcaatg aaacaccgga acctccgacc acctcctgaa tagtgggaga 660
 cacaccacga gcctgaagtt tgtccttcg

<210> 27
 <211> 471
 <212> DNA
 <213> Human

<400> 27

45 tcccagcggc atgaagtgtt agattggcca ggcctgtgac ctgggcttca tctccttcgt 60
 ccctctcgct cattggtggc accctgcttt gcctgtcctg ccaggacgag gcaccctaca 120
 agccctaacc caggcccgcc ccagggccac cagcaccact gcaaacaccg cacctgccta 180
 ccagccacca gctgcctaca aagacaatcg ggccccctca gtgacctcgg ccaccacagc 240
 gggtagcagg tgaacgacta cgtgtgagtc cccacagcct gcttctcccc tgggctgctg 300
 tgggctgggt cccggcgggg ctgtcaatgg aggcaggggt tccagcacia agttttacttc 360
 50 tgggcaattt ttgtatccaa ggaaataatg tgaatgcgag gaaatgtctt tagagcacag 420
 ggacagaggg ggaaataaga ggaggagaaa gctctctata ccaaagactg a

<210> 28
 <211> 929
 <212> DNA
 <213> Human

<400> 28

ggtgaactca gtgcattggg ccaatgggttc gacacaggct ctgccagcca caaccatcct 60
 gctgcttctg acgggttggc tgctgggtggg ctttcccttc actgtcattg gaggcattct 120
 tgggaagaac aacgccagcc cctttgatgc accctgtcgc accaagaaca tcgcccggga 180
 5 gattccaccc cagccctggg acaagtctac tgtcatccac atgactgttg gaggcttccct 240
 gcctttcagt gccatctctg tggagctgta ctacatcttt gccacagtat ggggtcggga 300
 gcagtaacact ttgtacggca tcctcttctt tgtcttcgcc atcctgctga gtgtgggggc 360
 ttgcatctcc attgcaactca cctacttcca gttgtctggg gaggattacc gctgggtggg 420
 gcgatctgtg ctgagtgttg gctccaccgg cctcttcato ttcctctact cagttttcta 480
 10 ttatgcccg cgctccaaca tgtctggggc agtacagaca gtagagtctt tcggctactc 540
 cttactcact gggttatgtct tcttccctcat gctgggcacc atctcctttt tttcttccct 600
 aaagttcatc cggatatctt atgttaacct caagatggac tgagtctgt atggcagaac 660
 tattgctgtt ctctcccttt ctctcatgcc tgttgaactc tcctaccagc ttctcttctg 720
 attgactgaa ttgtgtgatg gcattgttgc cttccctttt tccctttggg cattccttcc 780
 ccagagaggg cctggaaatt ataaatctct atcacataag gattatatat ttgaactttt 840
 15 taagttgcct ttagtttttg tcctgatttt tctttttaca attacaaaaa taaaatttat 900
 taagaaaaag aaaaaaaaaa aaaaaaaaaa
 <210> 29
 <211> 1775
 <212> DNA
 <213> Human
 20 <400> 29
 gaacgtgatg ggaacttttg gaggatgtct gagaaaaatgt ccgaagggat tttggccaac 60
 accagaaaaac gccaatgtcc taggaattcc ctcccaaaat gcttcccaaa aaattactca 120
 25 ttgacaattc aaattgcact tggctggcgg cagcccgggc ggccttcagt ccgtgtgggg 180
 cgcccgcggtg gccttctcct cgtaggactc cccaaactcg ttcactctgc gtttatccac 240
 aggataaagc caccgctggg acaggtagac cagaacaccc acgtcgtccc ggaagcaggc 300
 cagccgggtga gacgtgggca tgggtgatgat gaaggcaaaag acgtcatcaa tgaaggtgtt 360
 gaaagccttg taggtgaagg ccttccaggg cagatgtgcc actgacttca acttgtagtt 420
 cacaaagagc tggggcagca tgaagaggaa accaaaggca tagaccccggt tgacgaagct 480
 gttgattaac caggagtacc agctcttata tttgatattc aggagtgaat agacagcacc 540
 30 cccgacacag agaggtatga caagtaacttc atggcctgag tatcgtactc 600
 ctccggttttc ctctcagatt cgctgtaagt gccaaactga aattcgggca tcaggcctct 660
 ccaaaaaata gtcattcttca atgccttctt cactttccac agctcaatgg cggctccaac 720
 acccgccggg accagcacca gcaggtcgt ctgctcgtcc agcaggaaca gaaagatgac 780
 caccgtgctg aagcagcgcc agagcaactgc cttggtggac atgccgatca tgctcttctt 840
 35 cttcttccag aaactgatgt catttttaaa ggccaggaaa tcaaagagaa gatggaacgc 900
 tgcgacaaag aaggtcagcg ccaggaagta taagttggta tctacaaaaa ttcctttcac 960
 ctcatcagca tctttctctg aaaacccgaa ctgctgcagg gagtacacgg cgtcctgcat 1020
 gtggatccag aagcgcagcc gccccagtga gacctgtctg taggacacgg tgaggggcag 1080
 ctccgtgggtg gagcggttta tgaccatcag tccttccacg cggttgctga gctgtcgtat 1140
 gaacaggatg ggcaggtaat gcacggtttt cccagctggg atcatcttca tgtaccgatg 1200
 40 cacatcggca ggcagggagg acccgtcaaa gacaaagttg tccgccatca cgttcagcgc 1260
 cagccgcgggt cgccagtggg acaactggctc atccagggca ctgctcggct tcttctccgc 1320
 ctcgatctgc tgtgtatcag actcccggg gagcaggttg atttctctg gcttggggac 1380
 catgtagggtg gtcagaggac tgaccagggtg cacctgcttc ccgtcgtgcc acggcaggac 1440
 ccagcgtga tggaggaaga tgtaggcata cagcgtccca ttgtttctcg ttttcttttg 1500
 45 tacagaaaca ttaactgtcc tttcaaattt ggactccaca tcaaagtctt ccacattcaa 1560
 gaccaggtcg atgttgttct cagcaccag gtgggacctc gtcgtgggtg acacgtcag 1620
 ctgcagcttg ggccgcggcg ccaggtaggg ctggatgcag ttggcgtcgc cggagcacgg 1680
 gcgggtgtag acgatgccgt acatgaccca gcaggtgtgc accacgtaga ccacgaacac 1740
 gccaccacc aagctggtga aggagctgcg gccc
 <210> 30
 <211> 1546
 <212> DNA
 <213> Human
 50 <400> 30
 aaaataagta ggaatgggca gtgggtattc acattcacta caccttttcc atttgctaatt 60
 aaggccctgc caggctggga gggaattgtc cctgcctgct tctggagaaa gaagatattg 120

EP 1 586 333 A2

	acaccatcta	cgggcacccat	ggaactgctt	caagtgaacca	ttctttttct	tctgcccagt	180
	atttgcagca	gtaacagcac	aggtgtttta	gaggcagcta	ataattcact	tgttggttact	240
	acaacaaaa	catctataac	aacaccaaac	acagaatcat	tacagaaaaa	tgttggtcaca	300
5	ccaacaactg	gaacaactcc	taaaaggaa	atcaccaatg	aattacttaa	aatgtctctg	360
	atgtcaacag	ctactttttt	aacaagtaaa	gatgaaggat	tgaaagccac	aaccactgat	420
	gtcaggaaga	atgactccat	catttcaaac	gtaacagtaa	caagtgttac	acttccaaat	480
	gctgtttcaa	cattacaaa	ttccaaaacc	aagactgaaa	ctcagagtcc	aattaaaaaca	540
	acagaaat	caggtagtgt	tctacaacca	gatgcacac	cttctaaaa	tggtacatta	600
	acctcaatac	cagttacaat	tccagaaaa	acctcacagt	ctcaagtaat	aggcactgag	660
10	ggtggaaaaa	atgcaagcac	ttcagcaacc	agccggtctt	attccagtat	tattttgccg	720
	gtgggttattg	ctttgattgt	aataacactt	tcagtatttg	ttctggtggg	tttgtaccga	780
	atgtgctgga	aggcagatcc	gggcacacca	gaaaatggaa	atgatcaacc	tcagtctgat	840
	aaagagagcg	tgaagcttct	taccgttaag	acaatttctc	atgagtctgg	tgagcactct	900
	gcacaaggaa	aaaccaagaa	ctgacagctt	gaggaattct	ctccacacct	aggcaataat	960
	tacgcttaat	cttcagcttc	tatgcacca	gcgtggaaaa	ggagaaagtc	ctgcagaatc	1020
	aatcccga	tccataacctg	ctgctggact	gtaccagacg	tctgtcccag	taaagtgatg	1080
15	tccagctgac	atgcaataat	ttgatggaa	caaaaagaac	cccggggctc	tcctgttctc	1140
	tcacatttaa	aaattccatt	actccattta	caggagcgtt	cctaggaaaa	ggaatttttag	1200
	gaggagaatt	tgtgagcagt	gaatctgaca	gcccaggagg	tgggctcgct	gataggcatg	1260
	actttcctta	atgtttaaag	ttttccgggc	caagaatttt	tatccatgaa	gactttccta	1320
	cttttctcgg	tgtttcttata	ttacctactg	ttagtattta	ttgtttacca	ctatgttaat	1380
	gcagggaaaa	gtttgcacgtg	tattattaaa	tattaggtag	aaatcatacc	atgctacttt	1440
20	gtacatatata	gtatttttatt	cctgctttcg	tgttactttt	aataaataac	tactgtactc	1500
	aataactctaa	aaatactata	acatgactgt	gaaaatggca	aaaaaa		

<210> 31
 <211> 750
 <212> DNA
 <213> Human
 <400> 31

	cacttgggca	ccccattttt	ctaaaaaaat	ggaaatctgg	agggcaaaaa	aggtgtgctg	60
30	aaggggaagt	cctctgatgg	cccaaaaacc	ttcttccaaa	ctagtgtagg	aatggaatgg	120
	atagcaaatg	gatccttttt	ggcctccttt	ggagcatgcc	ttccctatct	tatccttggc	180
	cccactaaag	cagaacgtta	cggatatattc	tgtttttgcc	attggatgcc	tatctggcca	240
	aacagccttt	ccctaattgg	aaaatgcagt	cctgttttaa	acctttgatt	tacgactact	300
	tgtacatgct	tgetcattac	aattttgaca	ttttttacat	agtgaagacc	ccaaacatat	360
	cagtgaaaaca	tgacaagatc	ataaagaaca	gtatcatatt	attattttagt	cgcttttaca	420
35	gtggcaagcc	aattttgaaa	tatctcattt	aaaactcaga	cccaattcac	tgagttatac	480
	ttttaatagc	ttcctcagca	cactatttcc	catgcattaa	atatgataaa	ataatctatc	540
	actgcccatac	ggtcttgtaa	aaaggaagtc	tgaatacaga	gcccacaaca	ctaaaattgt	600
	ttttctagct	acaaaagtata	gcatcatcaa	cacagacacg	atgttgactc	cctgacaggt	660
	ggattggaaa	acggtgttta	aagagaagag	aacattttta	cataaatgtc	attaagaatc	720
	ccaaaggcct	tattttgtcac	caccgtcccg				

<210> 32
 <211> 1620
 <212> DNA
 <213> Human
 <400> 32

	gcaattcccc	cctcccacta	aacgactccc	agtaattatg	tttacaaccc	attggatgca	60
	gtgcagccat	tcataagaac	cttggtgccc	cagaaaaatc	tgtccttttt	ggtaccaaac	120
	ctgaggtctt	ttggaagata	atgtagaaaa	ccactaccta	ttgaaggcct	gttttggcta	180
	atctgtgcaa	actctgatga	tacctgcctt	atgtggattc	ttttccacac	tgcttttcatt	240
	tttaagtata	aagacttaga	aaactagaat	aatgctttta	caaataatta	aaagtatgtg	300
50	atgtttctggg	ttttttcctt	cttttttagaa	ccccgcctoc	atttaaaaaa	ttaaaaaaa	360
	aaaaaaaaact	tttaacattt	aaaaaataaa	aattaacaaa	atttcactta	ttccaggaca	420
	cgctggcatt	tggactcaat	gaaaagggca	ctaaaagaaa	ataaggctga	ctgaatgttt	480
	tcataatttt	tcacacaata	acagtccttt	tctatccagc	ttgccttcca	tttatctcta	540
	gggttagctt	ttcaggcaac	atccttggtc	attgcccaga	aagtacctga	gctatcagtg	600
	atttgaatgg	cacaggaaac	cgaatcacat	gggtgccctc	cccttggttt	tcaagtatct	660
55	tggagttgtg	cacaaaaatt	aggtcatgcc	ttcagtgctc	tgttctttta	acctaccctt	720
	tgacaatcag	gtgctaataga	ttgtatacta	ttaaaaccag	cacataagta	ttgtaaatgt	780

EP 1 586 333 A2

	gtgttctctcc	taggttggaa	gaaatgtctt	tccttctatc	tgggtcctgt	taaagcgggt	840
	gtcagttgtg	tcttttcacc	tcgatttgtg	aattaataga	attgggggga	gaggaaatga	900
	tgatgtcaat	taagtttcag	gtttggcatg	atcatcattc	tcgatgatat	tctcactttg	960
5	tcgcaaattc	gcccttatcg	taagaacaag	tttcagaatt	ttccctccac	tatacgactc	1020
	cagtatttat	tttacaatcc	attggatgag	tgcagcatta	taagaccttg	gtgccccagaa	1080
	aaatctgtcc	tttttggtag	caaacctgag	gtcttttggg	agataatgta	gaaaaccact	1140
	acctattgaa	ggcctgtttt	ggctaattctg	tgcacaaact	gatgatacct	gcttatgttg	1200
	attcttttcc	acactgcttt	cattttttaag	tataaagact	tagaaaacta	gaataatgct	1260
	tttacaataa	attaaaagta	tgtgatgttc	tgggtttttt	ccttcttttt	agaaccctgt	1320
10	atttaaacaa	gccttctttt	taagtcttgt	ttgaaattta	agtctcagat	cttctggata	1380
	ccaaatcaaa	aacccaacgc	gtaaaacagg	gcagtatattg	tgttcctaata	tttaaaaaagc	1440
	tttatgtata	ctctataaat	atagatgcat	aaacaacact	tcccttgag	tagcacatca	1500
	acatacagca	ttgtacatta	caatgaaaat	gtgtaactta	agggtattat	atatataaat	1560
	acatatatac	ctttgttaacc	tttatactgt	aaataaaaaa	gttgcttttag	tcaaaaaaaa	1620
15	<210> 33						
	<211> 2968						
	<212> DNA						
	<213> Human						
	<400> 33						
20	gaaaaagtag	aaggaaacac	agttcatata	gaagtaaaag	aaaacctga	agaggaggag	60
	gaggaggaag	aagaggaaga	agaagatgaa	gaaagtgaag	aggaggagga	agaggaggga	120
	gaaagtgaag	gcagtgaagg	tgatgaggaa	gatgaaaagg	tgtcagatga	gaaggattca	180
	gggaagacat	tagataaaaa	gccaaagtaa	gaaatgagct	cagattctga	atatgactct	240
	gatgatgac	ggactaaaaga	agaaagggt	tatgacaaaag	caaaacggag	gatttgagaaa	300
25	cggcgacttg	aacatagtaa	aaatgtaaac	accgaaaagc	taagagcccc	tattatctgc	360
	gtacttgggc	atgtggacac	aggggaagaca	aaaattctag	ataagctcog	tcacacacat	420
	gtacaagatg	gtgaagcagg	tggtatcaca	caacaaattg	gggccaccaa	tgttcctctt	480
	gaagctatta	atgaacagac	taagatgatt	aaaaattttg	atagagagaa	tgtacggatt	540
	ccaggaatgc	taattattga	tactcctggg	catgaatctt	tcagtaatct	gagaaataga	600
	ggaagctctc	tttgtgacat	tgccatttta	gttgttgata	ttatgcattg	tttgagccc	660
30	cagacaattg	agtctatcaa	ccttctcaaa	tctaaaaaat	gtcccttcat	tgttgactct	720
	aataagattg	ataggttata	tgatttgaaa	aagagtcctg	actctgatgt	ggctgctact	780
	ttaaagaagc	agaaaaagaa	tacaaaagat	gaatttgagg	agcgagcaaa	ggctattatt	840
	gtagaatttg	cacagcaggg	tttgaatgct	gctttgtttt	atgagaataa	agatccccgc	900
	acttttgtgt	cttttggtacc	taoctctgca	catactgggt	atggcatggg	aagtctgatc	960
	taccttcttg	tagagttaac	tcagaccatg	ttgagcaaga	gacttgacac	ctgtgaagag	1020
35	ctgagagcac	aggtgatgga	ggttaaagct	ctcccgggga	tgggcaccac	tatagatgtc	1080
	atcttgatca	atgggcgttt	gaaggaagga	gatacaatca	ttgttctctg	agtagaagg	1140
	cccattgtaa	ctcagattcg	agggcctcctg	ttacctcctc	ctatgaagga	attacgagtg	1200
	aagaaccagt	atgaaaagca	taaagaagta	gaagcagctc	agggggtaaa	gattcttgga	1260
	aaagacctgg	agaaaacatt	ggctggttta	ccctcctttg	tggcttataa	agaagatgaa	1320
	atccctgttc	ttaaagatga	attgatccat	gagtttaaagc	agacactaaa	tgctatcaaa	1380
40	ttagaagaaa	aaggagtcta	tgtccaggca	tctacactgg	gttctttgga	agctctactg	1440
	gaatttctga	aaacatcaga	agtgccctat	gcaggaatta	acattggccc	agtgcataaa	1500
	aaagatgtta	tgaaggcttc	agtgatgttg	gaacatgacc	ctcagtatgc	agtaattttg	1560
	gccttcgatg	tgagaattga	acgagatgca	caagaaatgg	ctgatagtgt	aggagttaga	1620
	attttttagtg	cagaaattat	ttatcattta	tttgatgcct	ttacaaaata	tagacaagac	1680
	tacaagaaac	agaaacaaga	agaattttaag	cacatagcag	tatttccctg	caagataaaa	1740
45	atcctccctc	agtacatttt	taattctcga	gatccgatag	tgatgggggt	gacggtgga	1800
	gcaggtcag	tgaaaacagg	gacacccatg	tgtgtcccaa	gcaaaaattt	tgttgacatc	1860
	ggaatagtaa	caagtattga	aataaaccat	aaacaagtgg	atgttgcaaa	aaaaggacaa	1920
	gaagtttgtg	taaaaaataga	acctatccct	ggtgagtcac	ccaaaatggt	tggaagacat	1980
	tttgaagcta	cagatattct	tgtagtaag	atcagccggc	agtccattga	tgactcaaaa	2040
	gactggttca	gagatgaaat	gcagaagagt	gactggcagc	ttattgtgga	gctgaagaaa	2100
50	gtatttgaaa	tcacttaatt	ttttcacatg	gagcaggaac	tggagttaaat	gcaatctgt	2160
	gttgtaaatat	cccaacaaaa	atcagacaaa	aaatggaaca	gacgtatttg	gacactgatg	2220
	gacttaagta	tggaagggaag	aaaaataggt	gtataaaatg	ttttccatga	gaaaccaaga	2280
	aacttacact	ggtttgacag	tggtcagttt	catgtcccca	cagttccaat	gtgctgttct	2340
	actcacctct	cccttcccca	acccttctct	acttggctgc	tgttttaaag	tttgcccttc	2400
	cccaaatttg	gattttttatt	acagatctaa	agctctttcg	atttttatact	gattaaatca	2460
55	gtactgcagt	atgttgattaa	aaaaaaaaaa	gcagattttg	tgattcttgg	gacttttttg	2520
	acgtaagaaa	tacttcttta	tttatgcata	ttcttcccac	agtgattttt	ccagcattct	2580
	tctgccatat	gccttttaggg	cttttataaa	atagaaaatt	aggcattctg	atatttcttt	2640

EP 1 586 333 A2

	agctgctttg	tgtgaaacca	tggtgtaaaa	gcacagctgg	ctgcttttta	ctgcttgtgt	2700
	agtcacgagt	ccattgtaat	catcacaatt	ctaaacccaa	ctaccaataa	agaaaaacaga	2760
	catccaccag	taagcaagct	ctgttaggct	tccatgggta	gtggtagctt	ctctcccaca	2820
	agttgtcctc	ctaggacaag	gaattatctt	aacaaactaa	actatccatc	acactacctt	2880
5	ggtagccag	cacctgggta	acagtaggag	attttataca	ttaatctgat	ctgtttaatc	2940
	tgatoggttt	agtagagatt	ttatacat				
	<210>	34					
	<211>	6011					
	<212>	DNA					
10	<213>	Human					
	<400>	34					
15							
	acggggcgcc	ggacgacccg	cacatcttat	cctccacgcc	ccactcgcac	tcggagcggg	60
	accgcccccg	actccccctc	gggcccggca	ctcgaggagt	gaggagagag	gccgcccggc	120
	cggtctgagc	cgagcgcagc	accccccgcg	cccccgccca	gaagtttggg	tgaaccgggc	180
	tgcocgggaga	aacttttttc	ttttttcccc	ctctcccggg	agagtctctg	gaggaggagg	240
	ggaaactcccc	cgcccccaag	ctcgtgggct	cggggtcgcg	cggccgcaga	aggggcgggg	300
20	tccgcccccg	aggggaggcg	cccccgggga	cccgagaggg	gggtgaggac	cgcgggctgc	360
	tggtgcggcg	gcggcagcgt	gtgcccccg	caggggaggc	gccgccccgc	tcccggcccc	420
	gctgcgagga	ggaggcggcg	gcggcgcagg	aggatgtact	tggtggcggg	ggacaggggg	480
	ttggccggct	gcgggcacct	cctggtctcg	ctgctggggc	tgctgctgct	gccggcgcgc	540
	tccggcacc	gggcgctggg	ctgctgccc	tgtgacgagt	ccaagtgcga	ggagcccagg	600
	aacgcgcccg	ggagcatcgt	gcaggcgctc	tgcggctgct	gctacacgtg	cgccagccag	660
25	gggaacgaga	gctgcggcgg	caccttcggg	atttacgaa	cctgcgaccg	ggggctgctg	720
	tgtctgtctc	tgatcgaggg	caatggcgac	tccctcacgc	agtacgaagc	gggcgtttgc	780
	gaagatgaga	actggactga	tgaccaactg	cttgggttta	aaccatgcaa	tgaaaacctt	840
	attgctggct	gcaatataat	caatgggaaa	tgtgaatgta	acaccattcg	aacctgcagc	900
	aatccccctt	agtttccaag	tcaggatatg	tgcccttcag	ctttaaagag	aattgaagaa	960
	gagaagccag	attgctccaa	ggcccgtctg	gaagtcaggt	tctctccacg	ttgtcctgaa	1020
30	gattctgttc	tgatcgaggg	ttatgctcct	cctggggagt	gctgtccctt	accagccgcg	1080
	tgcgtgtgca	accccccgag	ctgtctgcgc	aaagtctgcc	agccgggaaa	cctgaacata	1140
	ctagtgtcaa	aagcctcagg	gaagccggga	gagtgtgtg	acctctatga	gtgcaaacca	1200
	gttttcggcg	tggactgcag	gactgtggaa	tgccctactg	ttcagcagac	cgcgtgtccc	1260
	ccggacagct	atgaaactca	agtcaagact	actgcagatg	gttgctgtac	tttgcccaaca	1320
	agatgcgagt	gtctctctgg	cttatgtggg	ttccccgtgt	gtgaggtggg	atccactccc	1380
35	cgcatagtct	ctcgtggcga	tgggacacct	ggaaagtgtc	gtgatgtctt	tgaatgtgtt	1440
	aatgatacaa	agccagcctg	cgtatttaac	aatgtggaat	attatgatgg	agacatgttt	1500
	cgaatggaca	actgtcgggt	ctgtcgatgc	caagggggcg	ttgccatctg	cttcaccgcc	1560
	cagtgtgggt	agataaactg	cgagaggtac	tacgtgcccg	aaggagagtg	ctgccagctg	1620
	tgtgaagatc	cagtgtatcc	ttttaataat	cccgtgtggc	gctatgccaa	tgccctgata	1680
	cttgcccacg	gagacgggtg	gcgggaagac	gactgcacat	tctgccagtg	cgtcaacggt	1740
40	gaacgccact	gcgttgcgac	cgtctgcgga	cagacctgca	caaaccctgt	gaaagtgcct	1800
	ggggagtgtt	gccctgtgtg	cgaagaacca	accatcatca	cagttgatcc	acctgcatgt	1860
	ggggagtatt	caaactgcac	tctgacacgg	aaggactgca	ttaatgggtt	caaacgcgat	1920
	cacaatggtt	gtcggacctg	tcagtgcata	aacaccagg	aactatgttc	agaacgtaaa	1980
	caaggctgca	ccttgaactg	tccttcgggt	ttccttactg	atgccccaaa	ctgtgagatc	2040
	tgtgagtgcc	gcccaggcc	caagaagtgc	agaccataaa	tctgtgacaa	gtattgtcca	2100
45	cttggattgc	tgaagaataa	gcacggctgt	gacctgtgtc	gctgtaagaa	atgtccagag	2160
	ctctcatgca	gtaagatctg	ccccttgggt	ttccagcagg	acagtcacgg	ctgtctttatc	2220
	tgcaagtgca	gagaggcctc	tgcttcagct	gggccaccca	tcctgtcggg	cacttgtctc	2280
	accgtggatg	gtcatcatca	taaaaatgag	gagagctggc	acgatgggtg	ccgggaatgc	2340
	tactgtctca	atggacggga	aatgtgtgct	ctgatcacct	gcccggtgcc	tgccctgtggc	2400
	aacccccacca	ttcacctctg	acagtgtctg	ccatcatgtg	cagatgactt	tgtgggtgcag	2460
50	aagccagagc	tcagtactcc	ctccatttgc	cagcccccctg	gaggagaata	ctttgtggaa	2520
	ggagaaaacgt	ggaacattga	ctcctgtact	cagtgcacct	gccacagcgg	acgggtgtctg	2580
	tgtgagacag	aggtgtgccc	accgctgtct	tgccagaacc	cctcacgcac	ccaggattcc	2640
	tgtgcccac	aggtgtacaga	tcaacctttt	cggccttcct	tgtcccga	taacagcgta	2700
	cctaattact	gcaaaaatga	tgaaggggat	atatctctgg	cagctgagtc	ctggaagcct	2760
	gacgtttgta	ccagctgcat	ctgcattgat	agcgtaatga	gctgtttctc	tgagtcctgc	2820
55	ccttctgtat	cctgtgaaag	acctgtcttg	agaaaaggcc	agtgttgtcc	ctactgcata	2880
	aaagacacaa	ttccaaagaa	ggtgggtgtgc	cacttcagtg	ggaaggccta	tgccgacgag	2940

gagcgggtggg accttgacag ctgcacccac tgctactgcc tgcagggcca gaccctctgc 3000
 tcgaccgtca gctgcccccc tctgcccgtg gttgagccca tcaacgtgga aggaagttgc 3060
 tgcccaatgt gtccagaaat gtatgtccca gaaccaacca atatacccat tgagaagaca 3120
 aaccatcgag gagaggttga cctggaggtt cccctgtggc ccacgcctag tgaaaatgat 3180
 5 atcggtccatc tccctagaga tatgggtcac ctccaggtag attacagaga taacaggctg 3240
 caccocaagtg aagattcttc actggactcc attgcctcag ttgtggttcc cataattata 3300
 tgccctctcta ttataatagc attcctattc atcaatcaga agaaacagtg gataccactg 3360
 ctttgctggg atcgaaacacc aactaagcct tcttccttaa ataatcagct agtatctgtg 3420
 gactgcaaga aaggaaccag agtccaggtg gacagttccc agagaatgct aagaattgca 3480
 10 gaaccagatg caagattcag tggcttctac agcatgcaaa aacagaacca tctacaggca 3540
 gacaatttct accaaacagt gtgaagaaag gcaactagga tgaggtttca aaagacggaa 3600
 gacgactaaa tctgctctaa aaagtaaaact agaatttgtg cacttgctta gtggattgta 3660
 ttggattgtg acttgatgta cagcgctaag accttactgg gatgggctct gtctacagca 3720
 atgtgcagaa caagcattcc cacttttccct caagataact gaccaagtgt tttcttagaa 3780
 ccaaagtttt taaagtgtct aagatatatt tgccctgtaag atagctgtag agatatttgg 3840
 ggtggggaca gtgagtttgg atggggaaag ggggtgggag gtggtgttgg gaagaaaaat 3900
 15 ttgtcagctt ggctcgggga gaaacctggg cagttcagtg cagttcagtg gccacaggtg 3960
 tatttttttc ctattgctct gaagactgca ctgggtgctg caaagctcag gcctgaatga 4020
 gcaggaaaca aaaaaggcct tgcgacccag ctgccataac cactttagaa ctaccagacg 4080
 agcacatcag aaccttttga cagccatccc aggtctaaag ccacaagttt cttttctata 4140
 cagtcacaac tgcagtaggc agtgaggaag ccagagaaat gcgatagcgg catcttctta 4200
 aagcgggtta ttaaggatat atacagttac actttttgct gcttttattt tcttccaagc 4260
 20 caatcaatca gccagttcct agcagagtca gcacatgaac aagatctaag tcatttcttg 4320
 atgtgagcac tggagctttt tttttttaca acgtgacagg aagaggaggg agaggggtgac 4380
 gaacaccagg catttccagg ggctataatt cactgtttgt tggtgctttg ttctgttata 4440
 ttgttggttg ttcatagtgt ttgttgaagc tctagcttaa gaagaaactt tttttaaaaa 4500
 gactgttttg ggattctttt tctttattat atactgattc taaaaaatag aaactacttc 4560
 25 attttaattg tatattatct aagcaccttt gttgaagctc aaaaaaatg atgctctttt 4620
 aaacttttagc aattatagga gtattttatgt aactatctta tgcttcaaaa aacaaaagta 4680
 tttgtgtgca tgtgtatata atatatatat atatatatat atttatacac atacaattta 4740
 tgttttctctg ttgaatgtat ttttatgaga ttttaaccag aacaaaggca gataaacagg 4800
 cattccatag cagtgttttt gatcacttac aaattttttg aataacacaa aatctcattc 4860
 tacctgcagt ttaattggaa agatgtgtgt gtgagagtat gtatgtgtgt gtgtgtgtgt 4920
 30 gtgtgtgctg gcgcacgcac gccttgagca gtcagcattg cacctgctat ggagaagggt 4980
 attcctttat taaaatcttc ctcatttgga tttgctttca gttggttttc aatttgctca 5040
 ctggccagag acattgatgg cagttcttat ctgcatcact aatcagctcc tggatttttt 5100
 tttttttttt tcaaacaaatg gtttgaaaca actactggaa tattgtccac aataagctgg 5160
 aagtttggtg tagtatgcct caaatataac tgactgtata ctatagtggt aacttttcaa 5220
 acagccctta gcacttttat actaattaac ccatttgtgc attgagtttt cttttaaaaa 5280
 35 tgcttggttg gaaagacaca gataccaggt atgcttaacg tgaaaagaaa atgtgttctg 5340
 ttttgtaaag gaactttcaa gtattgttgt aaatacttgg acagaggttg ctgaacttta 5400
 aaaaaaatta atttattatt ataatacact aatttattaa tctgaagatt aaccattttt 5460
 ttgtcttaga atatcaaaaa gaaaaagaaa aaggtgttct agctgtttgc atcaaaggaa 5520
 aaaaagattt attatcaagg ggcaatattt ttatcttttc caaaataaat ttgttaatag 5580
 tacattacaa aaatagattg acatcagcct gatttagtata aattttgttg gtaattaatc 5640
 40 cattcctggc ataaaaagtc tttatcaaaa aaaattgtag atgcttgctt tttgtttttt 5700
 caatcatggc catattatga aaatactaac aggatatagg acaagggtga aattttttta 5760
 ttattatttt aaagatatga tttatcctga gtgctgtatc tattactctt ttacttttgt 5820
 tctgtttgtg ctcttgtaaa agaaaaatat aatttctctga agaataaaat agatatatgg 5880
 cacttgaggt gcacataggt tctacagttt gtttttgttt tcttcaaaaa agctgtaaga 5940
 gaattatctg caacttgatt cttggcagga aataaacatt ttgagttgaa atcaaaaaaa 6000
 45 a

<210> 34a
 <211> 1036
 <212> DNA
 <213> Human

50 <400> 34a

mylvagdrgl agcghllvsl lgllllpars gtralvcplc deskceepn rpgsivqgvc 60
 gccytcasqg nescgggtfgi ygtcdrqlrc virpplngds lteyeagvce denwtdddql 120
 55 gfkpcnenli agcniingkc ecntirtcsn pfefpsqdmc lsalkkrieee kpdcskarce 180
 vqfsprcped svliegyapp geccpplpsrc vcnpagclrk vcqpgnlnil vskasgkpgge 240

EP 1 586 333 A2

ccdlyeckpv fgvdcrvec ptvqgtacpp dsyetqvrllt adgcctlptr cecslgclcgf 300
 pvcevgstpr ivsrgdgtpg kccdvfecvn dtkpacvfnn veyydgdmfr mdncrfrcrcq 360
 ggvaicftaq cgeinceryy vpegeccpvc edpvypfnnp agcyanglil ahgdrwredd 420
 5 ctfcqcvnge rhcvatvcgq tctnpvkvpq eccpvceepi iitvdppacg elsncctltrk 480
 dcingfkrdh ngcrtccqcin tqelcserkq gctlncpfpgf ltdaqnccic ecrprpkkr 540
 piicdkycpl gllknkhgcd icrckkcpel scskicplgf qgdshgcllc kcreasasag 600
 ppilsgtclt vdghhhknee shwdgcrecy clngremcal itcpvpacgn ptihpgqccp 660
 scaddfvvqk pelstpsich apggeyfvge etwnidsctq ctchsgrvlc etevcppllc 720
 qnpsrtqdsc cpqctdgqfr pslsrnnsvp nyckndegdi flaaeswkp d vctscicids 780
 10 viscfesescp svscerpvlr kggccpycik dtipkkvvch fsgkayadee rwdldscethc 840
 yclqggtlcs tvscpplpcv epinvegsc pmcpemyvpe ptnipiekt hrgevdlevp 900
 lwptpsendi vhlprdmghl qvdyrdnrhl psedssldsi asvvvpiiic lsiiaaflfi 960
 nqkkqwipll cwyrtptkps slnnqlvsd ckkgttrvqvd ssqrmrliae pdarfsgfys 1020
 mqkqnhlqad nfyqtv

15 <210> 35
 <211> 716
 <212> DNA
 <213> Human

20 <400> 35

25 gcagtagctg gagtgtcctg cagggggaaa gcgaaccggg ccctgaagtc cggggcagtc 60
 acccggggct cctgggccc tctgccgggc tggggctgag cagcgatcct gctttgtccc 120
 agaagtccag agggatcagc cccagaacac accctcctcc ccgggacgcc gcagctttct 180
 ggaggctgag gaaggcatga agagtgggct ccacctgctg gccgactgag aaaagaattt 240
 ccagaactcg gtcctatatt acagattgag aaactatggt tcaagaagag aggacggggc 300
 ttgagggaat ctctgattc tctttatatg acctcaaact gaccatacta aacagtgtag 360
 aaggtctttt taaggctcta aatgtcaggg tctcccatcc cctgatgcct gacttgtaca 420
 gtcagtggtg agtagacggt ttctccacc caggggtgac tcagggggat gatctgggtc 480
 ccattctggt cttaagacc ccaacaaggg ttttttcagc tccaggatct ggagcctcta 540
 30 tctggttagt gtcgtaacct ctgtgtgct cccgttacc catctgtcca gtgagctcag 600
 ccccatacca cctaacaggg tggccacagg gattactgag ggtaagacc ttagaactgg 660
 gtctagcacc cgataagagc tcaataaatg ttgttcttt ccacatcaaa aaaaaa

35 <210> 36
 <211> 395
 <212> DNA
 <213> Human

<400> 36

40 ccaatacttc attcttcatt ggtggagaag attgtagact tctaagcatt ttccaaataa 60
 aaaagctatg atttgatttc caacttttaa acattgcatg tcttttgcca ttactacat 120
 tctccaaaaa aaccttgaaa tgaagaaggc cacccttaaa atacttcaga ggctgaaaaa 180
 atgattatta cattggaatc ctttagccta tgtgatattt cttaacttt gcactttcac 240
 gccagtaaaa accaaagtca gggttaacca tgctatttta caaaatgtta aaacccta 300
 tgcagttcct tttttaaatt attttaaaga ttacttaaca acattagaca gtgcaaaaaa 360
 agaagcaagg aaagcattct taattctacc atcct

45 <210> 37
 <211> 134
 <212> DNA
 <213> Human

50 <400> 37

cctcagagcg gccgcccggg caggtacttt taccaccgaa ttgttcaact gactttaaga 60
 aaccataaaa gctgcctggc tttcagcaac aggcctatca acaccatggt gactctccat 120
 aaggacacc gtgt

55 <210> 38
 <211> 644
 <212> DNA

EP 1 586 333 A2

<213> Human

<400> 38

```

5   aagcctgttg  tcatggggga  ggtggtggcg  cttggtggcc  actggcggcc  gaggtagagg  60
    cagtggcgct  tgagttggtc  gggggcagcg  gcagatttga  ggcttaagca  acttcttccg  120
    ggggaagagt  ccagtgagcg  cactgtttaca  attcaagatc  ttgatctata  tccatagatt  180
    ggaatattgg  tgggccagca  atcctcagac  gcctcactta  ggacaaatga  ggaaactgag  240
    gcttggtgaa  gttacgaaac  ttgtccaaaa  tcacacaact  tgtaaagggc  acagccaaga  300
    ttcagagcca  ggctgtaaaa  attaaaatga  acaaattacg  gcaaagtttt  aggagaaaga  360
10  aggatgttta  tgttccagag  gccagtcgtc  cacatcagtg  gcagacagat  gaagaaggcg  420
    ttcgcaccgg  aaaatgtagc  ttcccggtta  agtaccttgg  ccatgtagaa  gttgatgaat  480
    caagagggaat  gcacatctgt  gaagatgctg  taaaaagatt  gaaagctgaa  aggaagttct  540
    tcaaaggctt  ctttggaaaa  actggaagaa  aagcagttta  agcagtttct  gtgggtctaa  600
    gcagatggac  tcagaggttg  tggatgaaaa  actaaggacc  tcat

```

<210> 39

<211> 657

<212> DNA

<213> Human

<400> 39

```

20  ctttttgttt  gggttttcca  atgtagatgt  ctcagtgaaa  tgtgcagata  tactttgttc  60
    cttatatggg  caccagtgtt  aattatggac  aaatacatta  aaacaagggt  tcctggccca  120
    gcctcccatc  taatctcttt  gatactcttg  gaatctaagt  ctgaggagcg  atttctgaat  180
    tagccagtgt  tgtaccaact  ttctgttagg  aattgtatta  gaataacctt  tctttttcag  240
    acctgctcag  tgagacatct  tggggaatga  agtaggaaaa  tagacatttg  gtggaaaaac  300
    agcaaaatga  gaacattaaa  aagactcatt  caagtatgag  tataaagggc  atggaaattc  360
    tggctccttt  agcaaaatga  gaagaaaaaa  ttctgctcag  cagtattcac  tgtgttaaga  420
    ttttttgttt  tttacacgaa  tggaaaaaat  atgtgtaagt  ggatatagatt  ttaatcagct  480
    aacagtcact  ccagagattt  tgatcagcac  caattcctat  agtagtaagt  atttaaaagt  540
    taagaaatac  tactacattt  aacattataa  agtagagttc  tggacataac  tgaaaattag  600
    atgtttgctt  caatagaaat  ttgttcccac  ttgtattttc  aacaaaatta  tcggaac

```

<210> 40

<211> 1328

<212> DNA

<213> Human

<400> 40

```

35  acaattttta  aataactagc  aattaatcac  agcatatcag  gaaaaagtac  acagtgaagt  60
    ctggttagtt  tttgtaggct  cattatgggt  agggctcgta  agatgtatat  aagaacctac  120
    ctatcatgct  gtatgtatca  ctcatcccat  ttcatgttcc  catgcatact  cgggcatcat  180
    gctaatatgt  atccttttaa  gcactctcaa  ggaaacaaaa  gggcctttta  tttttataaa  240
    ggtaaaaaaa  attccccaaa  tattttgcac  tgaatgtacc  aaagggtgaag  ggacattaca  300
    atatgactaa  cagcaactcc  atcacttgag  aagtataata  gaaaatagct  tctaaatcaa  360
    acttccctca  cagtgccgtg  tctaccacta  caaggactgt  gcatctaagt  aataattttt  420
    taagattcac  tatatgtgat  agtatgatat  gcatttattt  aaaatgcatt  agactctctt  480
    ccattccatca  aatactttac  aggatggcat  ttaatacaga  tatttcgtat  ttccccact  540
    gctttttatt  tgtacagcat  cattaaacac  taagctcagt  taaggagcca  tcagcaacac  600
    tgaagagatc  agtagtaaga  attccatttt  cctcatcag  tgaagacacc  acaaattgaa  660
    actcagaact  atattttctaa  gcctgcattt  tcaactgatc  ataattttct  tagtaatat  720
    aagagacagt  ttttctatgg  catctocaaa  actgcatgac  atcactagtc  ttacttctgc  780
    ttaattttat  gagaagggtat  tcttcatttt  aattgctttt  gggattactc  cacatctttg  840
    tttatttctt  gactaatcag  attttcaata  gagtgaagtt  aaattggggg  tcataaaaagc  900
    attggattga  catatggttt  gccagcctat  gggtttacag  gcattgcccc  aacatttctt  960
    tgagatctat  atttataagc  agccatggaa  ttctatttat  gggatgtttg  caatcttaca  1020
    ttttatagag  gtcatatgca  tagttttcat  aggtgttttg  taagaactga  ttgctctcct  1080
    gtgagttaag  ctatgtttac  tactgggacc  ctcaagagga  ataccactta  tgttacactc  1140
    ctgcactaaa  ggcagctact  gcagtgtgaa  gaaatgttct  gaaaaagggt  tatagaaatc  1200
    tggaaataag  aaagggaagag  ctctctgtat  tctataattg  gaagagaaaa  aaagaaaaac  1260
    ttttaactgg  aaatgttagt  ttgtacttat  tgatcatgaa  tacaagtata  tatttaattt  1320
    tgaaaaaa

```

EP 1 586 333 A2

<210> 41
<211> 987
<212> DNA
<213> Human

5

<400> 41

	aacagagact	ggcacaggac	ctcttcattg	caggaagatg	gtagtgtagg	caggtaacat	60
	tgagctcttt	tcaaaaaagg	agagctcttc	ttcaagataa	ggaagtggta	gttatgggtg	120
10	taacccccgg	ctatcagtc	ggatgggtgc	cacccctcct	gctgtaggat	ggaagcagcc	180
	atggagtggg	agggaggcgc	aataagacac	ccctccacag	agcttggcat	catgggaagc	240
	tggtttctacc	tcttctctgg	tcctttgttt	aaaggcctgg	ctgggagcct	tccttttggg	300
	tgtctttctc	ttctccaacc	aacagaaaag	actgctcttc	aaaggtggag	ggtcttcatg	360
	aaacacagct	gccaggagcc	caggcacagg	gctgggggccc	tggaaaaagg	agggcacaca	420
	ggaggaggga	ggagctggta	gggagatgct	ggctttacct	aaggtctcga	aacaaggagg	480
15	gcagaatagg	cagaggcctc	tccgtcccag	gcccattttt	gacagatggc	gggacggaaa	540
	tgcaatagac	cagcctgcaa	gaaagacatg	tgttttgatg	acaggcagtg	tggccgggtg	600
	gaacaagcac	aggccttggg	atccaatgga	ctgaatcaga	accctaggcc	tgccatctgt	660
	cagccgggtg	acctgggtca	attttagcct	ctaaaagcct	cagtctcctt	atctgcaaaa	720
	tgaggcttgt	gatacctgtt	ttgaagggtt	gctgagaaaa	ttaaagataa	gggtatccaa	780
	aatagtctac	ggccatacca	ccctgaacgt	gcctaattct	gtaagctaag	cagggtcagg	840
20	cctggtttagt	acctggatgg	ggagagtatg	gaaaacatac	ctgccgcgag	ttggagttag	900
	actctgtctt	aacagttagc	tggcacacag	aaggcactca	gtaaataact	gttgaataaa	960
	tgaagttagc	atctgggtgtg	aaaaaaa				

<210> 42
<211> 956
<212> DNA
<213> Human

25

<400> 42

	cggacgggtg	ggcggacgcg	tgggtgcagg	agcaggggcg	ctgccgactg	ccccaaacca	60
30	ggaaggagcc	cctgagtcgc	cctgcgcctc	catccatctg	tccggccaga	gccggcatcc	120
	ttgcctgtct	aaagccttaa	ctaagactcc	cgccccgggc	tggccctgtg	cagaccttac	180
	tcagggggatg	tttacctgg	gctcggaag	ggagggggaag	gggcccggga	gggggcacgg	240
	caggcgtgtg	gcagccacac	gcaggcggcc	agggcggcca	gggacccaaa	gcaggatgac	300
	cacgcacctc	cacgccactg	cctcccccg	atgcatttgg	aaccaaagtc	taaactgagc	360
	tcgcagcccc	cgcgcctctc	ctccgcctcc	catcccgtt	agcgtctctg	acagatggac	420
35	gcaggccctg	tccagccccc	agtgcgctcg	ttccggtccc	cacagactgc	cccagccaac	480
	gagattgtctg	gaaaccaagt	caggccaggt	gggcccagaa	aagggccagg	tgcggcctgg	540
	ggggaaocga	tgctccgagg	actggactgt	ttttttcaca	catcgttgcc	gcagcgggtg	600
	gaaggaaagg	cagatgtaaa	tgatgtgttg	gtttacaggg	tatatatttt	ataccttcaa	660
	tgaattaatt	cagatgtttt	acgcaaggaa	ggacttacct	agtattactg	ctgctgtgct	720
	tttgatctct	gcttaccgtt	caagagggct	gtgcaggccg	acagtcgggt	accccatcac	780
40	tcgcaggacc	aaggggggcg	ggactgctgg	ctcacgcccc	gctgtgtcct	ccctcccctc	840
	ccttcccttg	gcagaatgaa	ttcgatgcgt	attctgtggc	cgccatctgc	gcagggtggg	900
	ggtattctgt	catttacaca	cgtcgttcta	attaaaaagc	gaattatact	ccaaaa	

<210> 43
<211> 536
<212> DNA
<213> Human

45

<400> 43

	aaataaacac	ttccataaca	ttttgttttc	gaagtctatt	aatgcaatcc	cacttttttc	60
50	cccctagttt	ctaaatgtta	aagagagggg	aaaaaaggct	caggatagtt	ttcacctcac	120
	agtgttagct	gtcttttatt	ttactcttgg	aaatagagac	tccattaggg	ttttgacatt	180
	ttgggaaccc	agttttacca	ttgtgtcagt	aaaacaataa	gatagtttga	gagcatatga	240
	tctaaataaa	gacatttgaa	gggttagttt	gaattctaaa	agtaggtaat	agccaaatag	300
	cattctcatc	ccttaacaga	caaaaaacta	tttgtcaaaa	gaattagaaa	aggtgaaaaa	360
	attttttcca	gatgaaactt	gtgccacttc	caattgacta	atgaaataca	aggagacaga	420
55	ctggaaaaag	tgggttatgc	cacctttaaa	accctttctg	gtaaatatta	tggtagctaa	480
	aggggtggtt	ccccggcacc	tggacctgga	caggtagggt	tccgtgggtta	accagt	

EP 1 586 333 A2

<210> 44
<211> 1630
<212> DNA
<213> Human

5

<400> 44

	ggggaggggac	gagtatggaa	cctgaaggt	agcaagtcca	ggcactggcc	tgaccatccg	60
	gctccctggg	caccaagtcc	caggcaggag	cagctgtttt	ccatcccttc	ccagacaagc	120
10	tctattttta	tcacaatgac	ctttagagag	gtctcccagg	ccagctcaag	gtgtcccact	180
	atccctctcg	gaggggaagag	gcaggaaaat	tctcccggg	tccctgtcat	gctactttct	240
	ccatcccagt	tcagactgtc	caggacatct	tatctgcagc	cataagagaa	ttataaggca	300
	gtgattttcc	ttaggcccag	gacttgggcc	tccagctcat	ctgttccttc	tggggccatt	360
	catggcaggt	tctgggctca	aagctgaact	ggggagagaa	gagatacaga	gctaccatgt	420
	gactttacct	gattgccctc	agtttggggt	tgcttatttg	gaaagagaga	gacaaagagt	480
15	tacttgttac	gggaaatatg	aaaagcatgg	ccaggatgca	tagaggagat	tctagcaggg	540
	gacaggattg	gctcagatga	cccctgaggg	ctcttccagt	cttgaaatgc	attccatgat	600
	attaggaagt	cggggggtgg	tggtggtggt	gggctagtgt	ggtttgaatt	tagggggccg	660
	tgagcttggg	tacgtgagca	gggtgttaag	ttagggtctg	cctgtatttc	tgggtccctt	720
	ggaaatgtcc	ccttcttcag	tgtcagacct	cagtcccagt	gtccatatcg	tgcccagaaa	780
	agtagacatt	atcctgcccc	atcccttccc	cagtgcactc	tgacctagct	agtgcctggt	840
20	gcccagtgac	ctgggggagc	ctggctgcag	gccctcactg	gttccctaaa	ccttggtggc	900
	tgtgattcag	gtccccaggg	gggactcagg	gaggaatatg	gctgagttct	gtagtttcca	960
	gagttggctg	gtagagcctt	ctagagggtt	agaatattag	cttcaggatc	agctgggggt	1020
	atggaatttg	ctgaggatca	aacgtatgta	ggtgaaagga	taccaggatg	ttgctaaagg	1080
	tgagggacag	tttgggtttg	ggacttacca	gggtgatgtt	agatctggaa	cccccaagtg	1140
	aggctggagg	gagttaaggt	cagtatggaa	gatagggttg	ggacagggtg	ccttggaatg	1200
25	aaagagtgc	cttagagggc	tccttgggcc	tcaggaatgc	tcctgctgct	gtgaagatga	1260
	gaaggtgtct	ttactcagtt	aatgatgagt	gactatatatt	accaaagccc	ctacctgtct	1320
	ctgggtccct	tgtagcacag	gagactgggg	ctaaggggcc	ctcccaggga	agggacacca	1380
	tcagcgctct	ggctgaggca	gtagcataga	ggatccattt	ctacctgcat	ttcccagagg	1440
	actagcagga	ggcagccttg	agaaaccggc	agttcccagg	ccagcgctct	gctgttctct	1500
	cattgtcaact	gccctctccc	caacctctcc	tctaaccac	tagagattgc	ctgtgtctct	1560
30	cctcttgctt	cttgtagaat	gcagctctgg	ccctcaataa	atgcttctct	cattcatctg	1620
	caaaaaaaaa						

<210> 45
<211> 169
<212> DNA
<213> Human

35

<400> 45

	tcttttgcct	ttagcttttt	atttttgtat	taacaggagt	cttattacac	ataggtctga	60
	taaaactggg	ttatgatctt	cagtctgatt	ccagtgctgc	ataactagat	aacgtatgaa	120
40	ggaaaaacga	cgacgaacaa	aaaagtaagt	gcttggaaga	cttagttga		

<210> 46
<211> 769
<212> DNA
<213> Human

45

<400> 46

	tgcaggtcac	atttactatc	ggcaataaaa	ggaagcaaa	cagtattaag	cagcgggtga	60
	atgtgtcgct	ttcacttttt	ataaagtgc	acataaaatg	tcataatttc	aaatttaaaa	120
	acataactcc	agttcttacc	atgagaacag	catgggtgat	acgaaggatc	ttcttgaaaa	180
50	aaacaaaaac	aaaaacaaaa	aacaatgatc	tcttctgggt	atcacatcaa	atgagataca	240
	aaggtgtact	aggcaatctt	agagatctgg	caacttattt	tatatataag	gcactctgtga	300
	ccaagagacg	ttatgaatta	aatgtacaaa	tgtattatgt	ataaatgtat	taaatgcaag	360
	cttcatataa	tgacaccaat	gtctctaagt	tgctcagaga	tcttgactgg	ctgtggccct	420
	ggcagctcc	tttccctgata	gtctgattct	gccttcatat	ataggcagct	cctgatcatc	480
	catgccagtg	aatgagaaaa	caagcatgga	atatataaac	tttaacatta	aaaaatgttt	540
55	tattttgtaa	taaaatcaaa	tttcccattg	aaaccttcaa	aaactttgca	gaatgagggt	600
	ttgatatatg	tgtacaagta	gtaccttctt	agtgcaagaa	aacatcatta	tttctgtctg	660
	cctgcctttt	tgtttttaaa	aatgaagact	atcattgaaa	caagtttgtc	ttcagtatca	720

ggacatgttg acggagagga aaggtaggaa agggttaggg atagaagcc

<210> 47
 <211> 2529
 <212> DNA
 <213> Human

<400> 47

10 tttagttcat agtaatgtaa aaccatttgt ttaattctaa atcaaatac tttcacaaca 60
 gtgaaaatta gtgactggtt aaggtgtgccc actgtacata tcatcatttt ctgactgggg 120
 tcaggacctg gtcctagtc acaaggggtg caggaggagg gtggaggcta agaacacaga 180
 aaacacacaa aagaaaggaa agctgccttg gcagaaggat gaggtggtga gcttgccgag 240
 ggatggtggg aaggggggtc cctgttgggg ccgagccagg agtcccaagt cagctctcct 300
 gccttactta gctcctggca gaggggtgagt ggggacctac gaggttcaaa atcaaattggc 360
 atttggccag cctggcttta ctaacagggt cccagagtgc ctctgttggc tgagctctcc 420
 15 tgggctcact ccatttcatt gaagagtcca aatgattcat ttctctaccc acaacttttc 480
 attattcttc tggaaaccca tttctgttga gtccatctga cttaagtcct ctctccctcc 540
 actagttggg gccactgcac tgaggggggt cccaccaatt ctctctagag aagagacact 600
 ccaggagccc ctgcaacttt gcggtatttc agaaggtgat aaaaagagca ctcttgagtg 660
 ggtgcccagg aatgtttaaa atctatcagg cacactataa agctgggtgt ttcttctac 720
 caagtggatt cggcatatga accacctact caatacttta tattttgtct gtttaaaccac 780
 20 tgaactctgg tgttgacagg taaaaaggag aagagatggg gactgtgaag aggggagggc 840
 ttccctcact ttccctcaaga tctttgtttc cataaactat gcagtcataa ttgagaaaaa 900
 gcaatagatg gggcttccca ccatttgttg gttattgtct ggggttagcca ggagcagtg 960
 ggatggcaaa gtaggagaga ggcccagagg aaagcccac tccctccagc tttgggtct 1020
 ccagaaagag gctggatttc tgggatgaag cctagaaggc agagcaagaa ctgttccacc 1080
 aggtgaacag tctacctgc ttggtacct agtccctcaa taagattcag aggaagaagc 1140
 25 ttatgaaact gaaaatcaaa tcaaggtatt gggaagaata atttccctc gattccacag 1200
 gaggaagac cacacaatat cattgtgtct gggctcccca aggccctgcc acctggcttt 1260
 acaaatcact aggggttgc tgggtggcag tcacatgctt cctgggtttt agcacacata 1320
 caaggagttt tcagggaact ctatcaagcc atacaaaaat cagggtcaca tgtgggtttc 1380
 ccctttcctt gcctcttcat aaaagacaac ttggcttctg aggatggtgg tcttttgcat 1440
 gcagttgggc tgacctgaca aagccccag tttcctgttg caggttcttg gagaggatgc 1500
 30 attcaagctt ctgcagccta ggggacagg ctgcttgttc agttattact gcctcggagc 1560
 tccaaatccc accaaagtcc tgactccagg tctttcctaa tgcacagtag tcagtctcag 1620
 cttcggcagt attctcggct gtatgttctc tggcagagag aggcagatga acatagtttt 1680
 agggagaaa ctgatgggaa acctgtgagt taagccacat gtctcaccag gaataattta 1740
 tgccaggaaa ccaggaaagtc attcaagttg ttctctgagg ccaaagacac tgagcacagc 1800
 ccagagccaa taaaagatct ttgagtctct ggtgaattca cgaagtgacc ccagctttag 1860
 35 ctactgcaat tatgattttt atgggacagc aatttcttgc atctctacag aggaagaaga 1920
 gggggagtgg gaggggaagg aaagagaaca gagcggcact gggatttgaa aggggaacct 1980
 ctctatctga ggagccccc ctggcttcag aagcaactta ccaaggggta tttaaagaca 2040
 tgaattttc cagaaatacc atttgggtga tcccttgtt tctgtaatat taaactcagg 2100
 tgaaattata ctctgacagt ttctctctt ctgcctcttc cctctgcaga gtcaggacct 2160
 gcagaactgg ctgaaacaag atttcatggt gtcacctatg agagatgact caatgccaa 2220
 40 gctgaagtt atagagtgt tacagcggtg gcgatattca ggggtcatcg ccaactgggtc 2280
 tcgagttcca aagctctgat gaagaaacaa gactccttga tgtgttactg atcccactga 2340
 ttccaggagt caagatttag caggaagcca aacaccagga gttgggggtg cacgtcacca 2400
 gtccagagcc ctgccacgga tgtacgcagg agcccagcat taggcaatca ggagccagaa 2460
 catgatcacc agggccacaa ataggaagag gcgtgacagg aactgctcgt ccacataacct 2520
 45 ggggtgtcc

<210> 48
 <211> 1553
 <212> DNA
 <213> Human

<400> 48

55 tttttttttt tttttgattt ctgggacaat taagctttat ttttcatata tatatatatt 60
 ttcatatata tatatacata catatataaa ggaacaatt tgcaaattta cacacctgac 120
 aaaaccatat atacacacat atgtatgcat acacacagac agacacacac acccgaagct 180
 ctagccaggc ccgttttcca tccctaagta ccattctctc atttggggcc ttctagggtt 240
 ggggcccctga gcttggtttg tagaagtttg gtgctaatat aaccatagct ttaatcccca 300
 tgaaggacag ttagaacctc atctttgtct gctcccgcgt gcctttcagt tttacgtgat 360

EP 1 586 333 A2

5 ccatcaagag ggctatggga gccaaagtga cacgggggat tgaggctaat tcacctgaac 420
 tcgaaaacag cgcccagctt cctcaccgca ggcacgcgtc ttttcttttt ttttctctga 480
 gacggagtct cgctgtgttg cccaggctgg agtgcagtgg cacggctctcg gctcactgca 540
 agctccacct cctggattca taccattctc ctgcttcagc ctcccgagta gctgggacta 600
 taggtgccaa ccactacgcc tagctaattt ttttttgtat ttttagtaga gacagggttt 660
 caccgtgtta gccaggatgg tctcgtctcg acttttgtat ccgcccgcct cggcctccca 720
 aagtgtctggg attacaggcg tgagccacca cacctggccc cggcacgtat cttttaagga 780
 atgacaccag ttcctggctt ctgaccaaag aaaaaatgtc acaggagact ttgaagaggc 840
 agacaggagg gtggtggcag caacactgca gctgcttctg gatgctgctg ggggtgctctc 900
 10 cggagcgggt gtgaacagcg cacttcaaca tgagcaggcg cctggctccg gtgtgtcctc 960
 acttcagtgg tgcacctgga tgggtggaagc cagccttttg ggcaggaaac cagctcagag 1020
 aggctaccca gctcagctgc tggcaggagc caggatatta cagccataat gtgtgtaaag 1080
 aaaaaacacg ttctgcaaga aactctccta ccgctcggg agactggggc tccttgcttg 1140
 ggatgagctt cactcaacgt ggagatggtg gtggactggt ccctgaaaag cgggccttgc 1200
 agggccaagt gagtcctca ggtcctaac ccagtggccc tctgaaaggg ggtgtgcagg 1260
 15 cgaggggagc aggaggtctc tctctagtcc ctttgagggc tttggctgag agaagagtga 1320
 gcagggagct gggaatggtc caggcaggga agggagctga agtgattcgg ggctaagtc 1380
 tcagatcgat gtatttctct ccctggtctc cgggagccct cttgtcaccg ctgctgccct 1440
 gcaggaggcc catctcttct gggagcttat ctgacttaac ttcaactaca agttcgcctc 1500
 tacgagaccg ggggtagcgt gatctcctgc ttccctgagc gcctgcacgg cag

 <210> 49
 20 <211> 921
 <212> DNA
 <213> Human

 <400> 49

 25 ctgtgggtccc agctactcag gaggctgagg cgggaggatt gcttgagccc aggagttgga 60
 tgttgagctg agccaagatc gcaccattgc cctccactct gggccacgga gcaataccct 120
 gtctcagaaa acaacaaca aaaaagcagaa acgctgaagg ggtcggttta cgggaaaacc 180
 gcctgtcaga aacttggct actcctaccc cagatcagtg gacctgggaa tgaggggttg 240
 tcccgggagg cttttctcca agctgttgcc accagaccgg ccatgggaac cctggccaca 300
 30 gaagcctccc ggggagttag ccagagcctg gaccgctgtg ctgatgtgtc tggggtggag 360
 ggaggggtgg gagtgtgcaa ggggtgtgtg gtgcccgggg ggtgttcatt ggcaagcatg 420
 tgcgtgcctg tgtgtgtgct tgcctctccc ctgcagccgt cgggtggtatc tccctccagc 480
 cccttcgcca cctctcagc attgtctgtc cacgtgagac tgcccagaga cagcagagct 540
 ccacgtgggt ttaaggggag acctttccct ggacctgggg gtctcgccgt atctcatgac 600
 cagggtgctaa atgaccogac atgcatcacc tgcccttcga tgaccaacct cctgtctccc 660
 gtcccgtgta cctgcccccg tggcgtctca cggatgatgcc tgctcctgac attggtgttc 720
 35 actgtagcaa actacattct ggatgggaat tttcatgtac atgtgtggca tgtggaaaat 780
 ttcaataaaa atggacttga tttagaaagc caaaaagctg tgtggtcctt ccagcacgga 840
 taactttgacc tcttgccctac aaccctctcc ttgggtccga ggctggtagc tttgttctact 900
 tcagatgggt gggggcgggt g

 <210> 50
 40 <211> 338
 <212> DNA
 <213> Human

 <400> 50

 45 atgatctatc tagatgcctt accgtaaaaat caaaacacaa aaccctactg actcattccc 60
 tcccttccag atattacccc atttctctac ttccattgt agccaaactt tccaaaaatt 120
 catgttctgt cttcatttcc tcatgttcaa cccaccctgt cttagctacc acccctcagt 180
 aacgacctag cctgggtaga aacaaatgtc agcatgata catactcaat gatccttctg 240
 cactgttgct attgtcatca ttccatggcc ttactttccc tctcagcgcc atttgctaca 300
 50 gtaagaaact ttctttcttg aattcttggg tctcttgg

 <210> 51
 <211> 1191
 <212> DNA
 <213> Human

 55 <400> 51

EP 1 586 333 A2

5 ctagcaagca ggtaaacgag ctttgtacaa acacacacag accaacacat ccggggatgg 60
 ctgtgtgttg ctagagcaga ggctgattaa acactcagtg tgttggctct ctgtgccact 120
 cctggaaaaa aatgaattgg gtaaggaaca gtttaataaga aaatgtgcct tgctaactgt 180
 gcacattaca acaaaagagct ggcagctcct gaaggaaaag ggcttgtgcc gctgccgttc 240
 aaacttgtca gtcaactcat gccagcagcc tcagcgtctg cctccccagc acaccctcat 300
 tacatgtgtc tgtctggcct gatctgtgca tctgctcgga gacgctcctg acaagtccgg 360
 aatttctcta tttctccact ggtgcaaaga gcggatttct ccttgccttct cttctgtcac 420
 ccccgctcct ctccccagc aggcctcctg atttatggta gctttggact tgcttccccg 480
 tctgactgtc cttgacttct agaatggaag aagctgagct ggtgaaggga agactccagg 540
 10 ccatcacaga taaaagaaaa atacaggaag aaatctcaca gaagcgtctg aaaatagagg 600
 aagacaaaact aaagcaccag catttgaaga aaaaggcctt gagggagaaa tggcttctag 660
 atggaatcag cagcggaaaa gaacaggaag agatgaagaa gcaaaatcaa caagaccagc 720
 accagatcca ggttctagaa caaagtatcc tcaggcttga gaaagagatc caagatcctg 780
 aaaaagctga actgcaaatc tcaacgaagg aagaggccat tttaaagaaa ctaaagtcaa 840
 ttgagcggac aacagaagac attataagat ctgtgaaagt ggaaagagaa gaaagagcag 900
 aagagtcaat tgaggacatc tatgctaata tccctgacct tccaaagtcc tacatacctt 960
 15 ctagggttaag gaaggagata aatgaagaaa acttgaagac tgaacaaaat aggaagcctt 1020
 tatatgccat ggaaattaaa gttgaaaaag acttgaagac tggagaaaagt acagttctgt 1080
 cttccaatac ctctggccat cagatgactt taaaaggtag aggagtaaaa gtttaagatg 1140
 atgggcaaaa gtccagtga ttcagttaaag tgctaatac aagttggagg t

<210> 52
 <211> 1200
 <212> DNA
 <213> Human

<400> 52

25 aacagggact ctactctat caaccccagg ctggagtcgg gtgogccac cctggctccc 60
 tgcaacctcc gcctcccagg ctcaagcaac tctcctgcct cagtcgctct agtagctggg 120
 actacaggca cacaccacca tgcccagcca atttttgcat tttttgtaga gacagggttt 180
 cgcttctgt ccaggccggc atcatatact ttaaatacatg ccagatgac tttataacct 240
 aatacaatat atcaggtttg tttaaaaata attgcttttt tattattttt gcattttttg 300
 30 accaacttta atgctatgta aatagttgtt atactgttgc ttaacaacag tatgacaatt 360
 ttggcttttt ctttgtatta ttttgtattt ttttttttta ttgtgtggtc tttttttttt 420
 ttctcagtggt tttcaattcc tcttgggttg aatccatgga tgcaaaaccc acagatatga 480
 agggctggct atatatgcat tgatgattgt cctattatat tagttataaa gtgtcattta 540
 atatgtagtg aaagtatttg tacagtggaa agagttagtg aaacataaaa catttggacc 600
 tttcaagaaa gtagcttgg tgaagttttt caccctcaaa ctatgtccca gtcagggttc 660
 tgctactaat tagctataat ctttgacaaa attacatcac ctttgagtct cagttgcctc 720
 35 acctgtaaaa tgaaagaact ggatactctc taaggctact tccagccctg tcattctata 780
 actctgttat gctgaggaag aaattcacat tgtgttaact gtatgagtca aactgaaaat 840
 gattattaaa ttgggaaaaa gccaatgtct tctcttagaa agctcaacta aatttgagaa 900
 gaataatctt ttcaattttt taagaattta aatattttta agggtttgac ctattttatt 960
 agagatgggg tctcactctg tcacccagac tggagtacag tggcacatc atagctcact 1020
 gctgcctcaa atcatgggc tcaagtgate ctctgcctc tgccctccaga gtagctgcga 1080
 40 ctatgggcat gtgccaccac gcctggctaa catttgtatt gacctattta tttattgtga 1140
 tttatatctt tttttttttt tctttttttt ttttttacia aatcagaaat acttattttg 1200

<210> 53
 <211> 989
 <212> DNA
 <213> Human

<400> 53

50 aagccaccac tcaaaaacttc ctatacattt tcacagcaga gacaagtga catttatttt 60
 tatgcctttc ttcctatgtg tatttcaagt ctttttcaaa acaaggcccc aggactctcc 120
 gattcaatta gtccttgggc tggctcgactg tgcaggagtc caggagcct ctacaaatgc 180
 agagtgaact tttaccaaca taaaccctag atacatgcaa aaagcaggac ccttccctca 240
 ggaatgtgcc atttcagatg cacagcacc atgcagaaaa gctggaattt tcttggaaac 300
 cgactgtgat agagggtgctt acatgaacat tgctactgtc tttctttttt tttgagacag 360
 gtttcgcttg tgcccaggct gagtgcattg cgtgatctca ctactgcaa ttccacctcc 420
 55 aggttcaagc atttctctgc tcagcctcct agtagctggg ttacaggcac tgccaccatg 480
 ccggctaatt ttgtattttt gtagagatgg atttctccat ttggtcaggc ggtctcgaa 540
 cccaacctca gtgatctgcc acctcagcct cctaagtgtt ggattacagg atgagccacc 600

EP 1 586 333 A2

cgaccggcca ctactgtctt tctttgaccc ttccagtttc gaagataaag aggaaataat 660
 ttctctgaag tacttgataa aattttccaaa caaaacacat gtccacttca ctgataaaaa 720
 atttaccgca gtttggcacc taagagtatg acaacagcaa taaaaagtaa tttcaaagag 780
 ttaagatttc ttcagcaaaa tagatgattc acatcttcaa gtcttttttg aaatcagtta 840
 5 ttaatatatt tctttcctca tttccatctg aatgactgca gcaatagttt tttttttttt 900
 tttttttttt ttgcgagatg gaatctcgct ctgtcgccca gcgggagtg cactggcgcaa 960
 gcccggtcca ccgcaatctc tgccacccg

<210> 54
 <211> 250
 10 <212> DNA
 <213> Human

<400> 54

catttcccca ttggtcctga tgttgaagat ttagttaaag aggctgtaag tcaggttcga 60
 gcagaggcta ctacaagaag tagggaaatca agtccctcac atgggctatt aaaactaggt 120
 agtggtggag tagtgaaaaa gaaatctgag caacttcata acgtaactgc ctttcaggga 180
 aaagggcatt ctttaggaac tgcattctggt aacccacacc ttgatccaag agctagggaa 240
 acttcagttg

<210> 55
 20 <211> 2270
 <212> DNA
 <213> Human

<400> 55

gcgcccccca gcagcgcccg cgccctccgc gccttctccg ccgggacctc gagcgaaaga 60
 ggcccgcgcg ccgcccagcc ctgcctcccc tgcccacccg gcacacccgc ccgccacccc 120
 gaccccgctg cgcacggcct gtccgctgca caccagcttg ttggcgtctt cgtcgccgcg 180
 ctgcgcccg gctactcctg cgcgcacaaa tgagctcccc catcgccagg gcgctcgctt 240
 tagtcgtcac ccttctccac ttgaccaggc ttggcgtctc cacctgcccc gctgcctgcc 300
 actgccccct ggaggcgcgc aagtgcgcgc cgggagtcgg gctgggtccg gacggtgcg 360
 30 gctgctgtaa ggtctgcgc aagcagctca acgaggactg cagcaaaaacg cagccctgcg 420
 accacaccaa cgggctggaa tgcaacttcg gcgccaaagt caccgctctg aaggggatct 480
 gcagagctca gtcagagggc agaccctgtg aatataactc cagaatctac caaacggggg 540
 aaagtttcca gcccaactgt aaacatcagt gcacatgtat tgatggcgcc gttgggtgca 600
 ttctctgtgt tcccaagaa ctatctctcc ccaacttggg ctgtcccaac cctcggtcgg 660
 tcaaagttac cgggcagtg gcgaggagt gggctctgtg cgaggatagt atcaaggacc 720
 35 ccatggagga ccaggacggc ctccctggca aggagctggg attcgatgcc tccgaggtgg 780
 agttgaacgag aaacaatgaa ttgattgcag ttggaaaagg cagctcactg aagcggctcc 840
 ctgttttttg aatggagcct cgcactctat acaacccttt acaaggccag aaatgtattg 900
 ttcaaacaaac ttcatggttc cagtgcctca agacctgtgg aactggatc tccacacgag 960
 ttaccaatga caaccctgag tgccgccttg tgaaagaaac ccggatttgt gaggtgcggc 1020
 cttgtggaca gccagtgtac agcagcctga aaaagggcaa gaaatgcagc aagaccaaga 1080
 40 aatcccccca accagtcagg ttactttacg ctggatgttt gagtgtgaag aaataccggc 1140
 ccaagtactg cggttcctgc gtggacggcc gatgctgcac gccccagctg accaggactg 1200
 tgaagatgcg gttccgctgc gaagatgggg agacattttc caagaacgtc atgatgatcc 1260
 agtctgcaa atgcaactac aactgcccgc atgccaatga agcagcgttt cccttctaca 1320
 ggctgttcaa tgacattcac aaatttaggg actaaatgct acctgggttt ccagggcaca 1380
 cctagacaaa caaggagaa gagtgtcaga atcagaatca tggagaaaat gggcgggggg 1440
 45 ggtgtgggtg atgggactca ttgtagaaag gaagccttgc tcattcttga ggagcattaa 1500
 ggtatttcga aactgccaag ggtgctggtg cggatggaca ctaatgcagc cacgattgga 1560
 gaatactttg cttcatagta ttggagcaca tgttactgct tcatttttga gcttgtggag 1620
 ttgatgactt tctgttttct gtttgtaaat tatttgctaa gcataatttc tctaggtctt 1680
 ttctcttttg ggtttctaca gtcgtaaaag agataataag attagttgga cagttttaaag 1740
 50 cttttattcg tcctttgaca aaagttaaag ggaggcatt ccatcccttc ctgaaggggg 1800
 aactccatg agtgtctgtg agaggcagct atctgcactc taaactgcaa acagaaatca 1860
 ggtgttttaa gactgaatgt tttatttata aaaatgtagc ttttggggag ggaggggaaa 1920
 tgtaatactg gaataatttg taaatgattt taattttata ttcagtgaag agattttatt 1980
 tatggaatta accatttaat aaagaaatat ttacctaata tctgagtgtg tgccattcgg 2040
 tattttttaga ggtgctccaa agtcattagg aacaacctag ctcacgtact caattattca 2100
 aacaggactt attgggatac agcagtgaat taagctatta aaataagata atgattgctt 2160
 55 ttataccttc agtagagaaa agtcttttga tataaagtaa tgtttaaaaa acatgtattg 2220
 aacacgacat tgtatgaagc acaataaaga ttctgaagct aaaaaaaaaa

<210> 56
 <211> 1636
 <212> DNA
 5 <213> Human

 <400> 56

 10 cttgaatgaa gctgacacca agaaccgcgg gaagagcttg ggcccaaagc aggaaaggga 60
 agcgctcgag ttggaaagga accgctgctg ctggccgaac tcaagcccgg gcgccccac 120
 cagtttgatt ggaagtccag ctgtgaaacc tggagcgctg ccttctcccc agatggctcc 180
 tggtttgctt ggtctcaagg acactgcacg gtcaaaactga tcccctggcc gttggaggag 240
 cagttcatcc ctaaaagggt tgaagccaaa agcogaagta gcaaaaatga gacgaaaggg 300
 cggggcagcc caaaagagaa gacgctggac tgtggtcaga ttgtctgggg gctggccttc 360
 agcccgtggc cttccccacc cagcaggaag ctctgggcac gccaccacc ccaagtgcc 420
 gatgtctctt gcctgggtct tgctacggga ctcaacgatg ggcatatcaa gatctgggag 480
 15 gtgcagacag ggctcctgct tttgaatctt tccggccacc aagatgtcgt gagagatctg 540
 agcttcacac ccagtggcag tttgattttg gtctccgctg cacgggataa gactcttcgc 600
 atctgggacc tgaataaaca cggtaaacag attcaagtgt tatcgggcca cctgcagtgg 660
 gtttactgct gttccatctc ccagactgac agcatgctgt gctctgcagc tggagagaag 720
 tcggctcttc tatggagcat gaggtcctac acgttaattc ggaagctaga gggccatcaa 780
 20 agcagtgttg tctcttgtag cttctcccc gactctgccc tgcctgtcac ggcttcttac 840
 gataccaatg tgattatgtg ggacccttac accggcgaaa ggctgaggtc actccaccac 900
 acccaggttg accccgccat ggatgacagt gacgtccaca ttagctcact gagatctgtg 960
 tgcttctctc cagaaggctt gtaccttgcc acgggtggcag atgacagact cctcaggatc 1020
 tgggcccctg aactgaaaac tcccattgca tttgtcctta tgaccaatgg gctttgtctg 1080
 acatttttcc cacatgggtg agtcattgac acagggacaa gagatggcca cgtccagttc 1140
 25 tggacagctc ctagggtcct gtctcactg aagcacttat gccggaaagc ccttcgaagt 1200
 ttcttaacaa cttaccaagt cctagcactg ccaatcccca agaaaatgaa agagtctctc 1260
 acatacagga ctttttaagc aacaccacat cttgtgcttc tttgtagcag ggtaaatcgt 1320
 cctgtcaaaag ggagttgctg gaataatggg ccaaaccatct ggtcttgcat tgaatatgca 1380
 30 tttctttggg attgtgaata gaattgtgca aaaccagatt ccagtgtaca taaaagaatt 1440
 tttttgtctt taaatagata caaatgtcta tcaactttta tcaagttgta acttatattg 1500
 aagacaattt gatacataat aaaaaattat gacaatgtcc tgggaaaaaa aaaatgtaga 1560
 aagatgggtg aggggtggat ggatgaggag cgtggtgacg ggggcctgca gcgggttggg 1620
 gacctgtgc tgcgtt

 <210> 57
 <211> 460
 <212> DNA
 35 <213> Human

 <400> 57

 40 ccatgtgtgt atgagagaga gagagatttg gagggagagg gagctcacta gcgcatatgt 60
 gcctccaggg ggctgcagat gtgtctgagg gtgagcctgg tgaaagagaa gacaaaagaa 120
 tggaatgagc taaagcagcc gcctgggggtg ggaggccgag cccattttgta tgcagcaggg 180
 ggagaggacc cagcaaggga gcctccattc ccaggactct ggaggagct gagaccatcc 240
 atgcccgtag agccctccct cacactccat cctgtccagc cctaattgtg caggtgggga 300
 aactgaggct gggaagtcac atagcaagt actggcagag ctgggactgg aacccaacca 360
 gcctcctaga ccacggttct tcccatcaat ggaatgctag agactccagc caggtgggta 420
 45 ccgagctcga attcgtaatc atggtcatag ctgtttcctg

 <210> 58
 <211> 1049
 <212> DNA
 50 <213> Human

 <400> 58

 55 atctgatcaa gaatacctgc cctggctcact ctgcggatgt ttctgtccac ttgttcacat 60
 tgaggaccaaa gatatacctt tttacagagg cacttggttg gtotaacaca gacacotcca 120
 tgacgacatg ctggctcaca ttttgagatt ctgcagaagt cccctctcca gcttgacta 180
 cagcagcact ttcccggtgg ggtgcagtag ccgtttcgac agagcctgga gcactctgaa 240
 gtcagtgtct gtgcaggttg taccgtggct ctgcattcct caggcattaa aggtcttttg 300
 ggatctacaa ttttgtagag ttttccattg tgagtctggg tcatactttt actgcttgat 360

5 aaaaatgtaaa cttcacctag ttcattcttct ccaaattccca agatgtgacc ggaaaagtag 420
 cctctacagg acccactagt gccgacacag agtgggtttt cttgccactg ctttgtcaca 480
 ggacttttgc ggagagttag gaaattccca ttacgatctc caaacacgta gcttccatac 540
 aatcttttctg actggcagcc ccggtatata aatccacca ccaaaggacc attactgaat 600
 ggcttgaatt ctaaaagtga tggctcactt tcataatctt tcccccttat tatctgtaga 660
 attctggctg atgatctgtt ttttccattg gagtctgaac acagtatcgt taaattgatg 720
 tttatatcag tgggatgtct atccacagca catctgcctg gatcgtggag cccatgagca 780
 aacacttcgg ggggctgggt ggtgctgttg aagtgtgggt tgctccttgg tatggaataa 840
 ggcacgttgc acatgtctgt gtccacatcc agccgtagca ctgagcctgt gaaatcactt 900
 10 aacccatcca tttcttccat atcatccagt gtaatcatcc catcaccaag aatgatgtac 960
 aaaaacccgt cagggccaaa gagcagttgc cctcccagat gctttctgtg gaggttctgca 1020
 acttcaagaa agactctggc tgttctcaa

<210> 59

<211> 747

15 <212> DNA

<213> Human

<400> 59

20 tttttcaaatt cacatatggc ttcttttgacc ccatcaaata actttatttca cacaaacgtc 60
 ccttaatttta caaagcctca gtcattcata cacattaggg gatccacagt gttcaaggaa 120
 cttaaatata atgtatcata ccaaccacaag taacccaagt acaaaaaata ttcataataa 180
 gttggttcaca cgtaggctct agattaccag cttctgtgca aaaaaaggaa atgaagaaaa 240
 atagatttat taactagtat tggaaactaa ctttgtgcct ggcttaaaac ctccctcacg 300
 ctcgtctgtc ccacacaaat gtttaagaag tcaactgcaat gtactccccg gctctgatga 360
 25 aaagaagccc ctggcacaaa agattccagt gcccctgaag aggctccctt cctcctgtgg 420
 gctctcctag aaaaccagcg ggacggcctc cctgctgata ccgtctataa ccttaggggg 480
 ccctcgggca ggcaacggca gtggactcat ctcggtgatg gctgtagatg ctaacactgg 540
 ccaattcaat gccacaccta ctggttaccc tttgagggca tttctccaga cagaagcccc 600
 ttgaagccta ggtagggcag gatcagagat acaccctgtt ttgtctcgaa gggctccaca 660
 30 gcccagtagc acatgcttgc agaagtagta tctctggact tctgcctcca gtcgaccggc 720
 cgcgaaatta gtagtaatat cggccgc

35

Claims

1. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
2. Pharmaceutical compositions comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
3. Pharmaceutical compositions comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium.
4. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
5. Pharmaceutical compositions comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.

6. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems.

7. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.

8. Pharmaceutical compositions comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

9. Pharmaceutical compositions according to claims 1-8 which are intended for simultaneous or separate sequential therapeutical application.

10. Pharmaceutical compositions according to claims 1-8 which comprise as compound I at least one of

- a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

11. Pharmaceutical compositions according to claims 1-8 which comprise as compound II at least one of


- g) compounds which inhibit receptor tyrosine kinase activity,
- h) compounds which inhibit ligand binding to receptors,
- i) compounds which inhibit activation of intracellular signal pathways of the receptors,
- j) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- k) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- l) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

12. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

13. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II Seq. ID Nos. 34a

14. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTFconjugate.

15. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one small molecule of general formula I



in which


r
n
R₃ und R₄

has the meaning of 0 to 2,

has the meaning of 0 to 2;

a) each independently from each other have the meaning of lower alkyl,


b) together form a bridge of general partial formula II,



wherein the binding is via the two terminal C- atoms, and

m has the meaning of 0 to 4; or

c) together form a bridge of partial formula III



wherein one or two of the ring members T₁, T₂, T₃, T₄ has the meaning of nitrogen, and each others have the meaning of CH, and the binding is via the atoms T₁ and T₄;

G has the meaning of C₁-C₆ - alkyl, C₂ - C₆ - alkylene or C₂ - C₆ - alkenylene; or C₂ - C₆ - alkylene

A, B, D, E and T

Q

 R_1 and R_2


X

Y

Z

or C_3 - C_6 -alkenylene, which are substituted with acyloxy or hydroxy; $-\text{CH}_2\text{-O-}$, $-\text{CH}_2\text{-S-}$, $-\text{CH}_2\text{-NH-}$, $-\text{CH}_2\text{-O-CH}_2\text{-}$, $-\text{CH}_2\text{-S-CH}_2\text{-}$, $-\text{CH}_2\text{-NH-CH}_2\text{-}$, oxa ($-\text{O-}$), thia ($-\text{S-}$) or imino ($-\text{NH-}$), independently from each other have the meaning of N or CH, with the proviso that not more than three of these Substituents have the meaning of N, has the meaning of lower alkyl, lower alkyloxy or halogene, independently from each other have the meaning of H or lower alkyl, has the meaning of imino, oxa or thia; has the meaning of hydrogene, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if more than one rest Z is present ($m \geq 2$), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single or double bonds; or an N-oxide of said compound, wherein one ore more N-atoms carry an oxygene atom, or a salt thereof,

and/or a compound of genaral formula IV




in which



A

W

Z

has the meaning of group $=\text{NR}^2$,
has the meaning of oxygen, sulfur, two hydrogen atoms or the group $=\text{NR}^8$,
has the meaning of the group $=\text{NR}^{10}$ or $=\text{N-}$, $-\text{N}(\text{R}^{10})\text{-(CH}_2\text{)}_q\text{-}$, branched or unbranched C_{1-6} -Alkyl or is the group

or A, Z and R^1 together form the group



m, n and o

has the meaning of 0 - 3,

q

has the meaning of 1 - 6,

R_a, R_b, R_c, R_d, R_e, R_f

independently from each other have the meaning of hydrogen, C₁₋₄ alkyl or the group =NR¹⁰, and/or R_a and/or R_b together with R_c and/or R_d or R_c together with R_e and/or R_f form a bound, or up to two of the groups R_a-R_f form a bridge with each up to 3 C-atoms with R¹ or R²,

X

has the meaning of group =NR⁹ or =N-,

Y

has the meaning of group -(CH₂)_p,

p

has the meaning of integer 1-4,

R¹

has the meaning of unsubstituted or optionally substituted with one or more of halogene, C₁₋₆-alkyl, or C₁₋₆-alkyl or C₁₋₆-alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,

R²


has the meaning of hydrogen or C₁₋₆-alkyl, or form a bridge with up to 3 ring atoms with R_a-R_f together with Z or R₁,

R³

has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of für halogen, C₁₋₆-alkyl, C₁₋₆-alkoxy or hydroxy,

R⁴, R⁵, R⁶ and R⁷


independently from each other have the meaning of hydrogen, halogene or C₁₋₆-alkoxy, C₁₋₆-alkyl or C₁₋₆-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogene, or R⁵ and R⁶ together form the group



R⁸, R⁹ and R¹⁰

independently from each other have the meaning of hydrogen or C₁₋₆-alkyl, as well as their isomers and salts,



and/ or a compound of general formula V




V,

in which


R¹ has the meaning of group



in which R⁵ is chloro, bromo or the group -OCH₃,



in which R⁷ is -CH₃ or chloro,




in which R^8 is $-\text{CH}_3$, fluoro, chloro or $-\text{CF}_3$

in which R^4 is fluoro, chloro, bromo, $-\text{CF}_3$, $-\text{N}=\text{C}$, $-\text{CH}_3$, $-\text{OCF}_3$ or $-\text{CH}_2\text{OH}$

in which R^6 is $-\text{CH}_3$ or chloro

R^2 has the meaning of pyridyl or the group



and

R^3 has the meaning of hydrogen or fluoro, as well as their isomers and salts.

16. Pharmaceutical compositions according to claim 15 which comprise as compound I and/or II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate

17. Pharmaceutical compositions according to claims 1-16 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II.

18. Pharmaceutical compositions according to claims 1-17 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/or L19 scFv-tTF conjugate.

19. Pharmaceutical compositions according to claims 1-17 which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/or scFv-tTF conjugate.

20. Pharmaceutical compositions according to claims 1-17 which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/or mAB 4301-42-35.

21. Pharmaceutical compositions according to claims 1-17 which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

22. Use of pharmaceutical compositions according to claims 1-21, for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage

of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

5

10

15

20

25

30

35

40

45

50

55




Fig. 1




Fig. 2





Fig. 3

**Fig. 4**




Fig. 5




Fig. 6